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CHAPTER I 
 
INTRODUCTION 
When considering both recommended and excessive medication dosages, almost 
all drugs have potentially serious adverse effects.  Adverse effects (AEs) are any harmful 
or unintended reactions to medication.  AEs can occur at doses normally used for 
treatment or because of overdose. Due to known limitations in premarketing medication 
trials (1–3), identification of adverse effects requires vigilant post-marketing surveillance.  
Agencies and investigators have recognized the potential for Electronic Medical Record 
Systems (EMRs) to characterize clinical correlations in large numbers of patients using 
prescription medications. 
This thesis project explores one aspect of using EMRs to detect single drug 
ingredient AEs – specifically, the feasibility of mining History and Physical (H&P) exam 
notes to detect concurrent mentions of single drug ingredients and clinical findings 
(including both symptoms and diseases).  In the remainder of this document, the term 
―drug‖ will refer to a single (active) drug ingredient (as opposed to a multi-component 
―combination‖ medication or an inert ingredient), unless otherwise stated. Our approach 
identifies drug and finding concepts using Natural Language Processing (NLP) of clinical 
text.  We hypothesize (based on previous work (2; 4–6)) that drug-finding pairs occurring 
in a higher-than expected number of records signify an underlying relationship between 
drug and finding.  If one can distinguish which pairs occur for known reasons, then one 
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can postulate that the remaining pairs occur for unknown reasons -- especially previously 
unrecognized potential adverse effects. 
Our project involved three phases. In Chapter III of this thesis, I describe the 
creation and evaluation of a knowledge base (KB) of known drug-finding pairs.  I 
developed this KB from multiple existing reference sources containing structured data. I 
used automated methods to extract, reformat, and combine the information.  In Chapter 
IV, I describe the extraction of drug-finding pairs from a corpus of de-identified H&P 
notes using NLP. Further processing required generalization of specific drug terms (e.g., 
mapping a brand name or a specific dose form to a common generic drug descriptor).  I 
calculated statistical measures of the strength of correlation between drug and finding 
concepts that appeared across large numbers of notes.  Finally, I discuss application of 
the (Chapter III) drug-finding KB to categorize the (Chapter IV) correlations as either 
known and/or unknown drug-finding correlations. I discuss the project results and the 
limitations of this study.  
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CHAPTER II 
 
BACKGROUND 
Introduction 
Most drugs have potentially serious, medication-specific adverse effects (AEs) at 
therapeutic or excessive doses (we detail our definition of AE in Figure 1).  The U.S. 
Food and Drug Administration (FDA) requires multi-phase clinical testing (described 
below) in an attempt to ensure efficacy and safety of prescription medications sold in the 
marketplace.  Due to known limitations in premarketing clinical trials (1–3), 
identification of adverse effects also requires vigilant post-marketing surveillance.  Some 
AEs remain unknown until after a drug has been approved for clinical use and used by 
large numbers of people. 
After extensive in vitro and animal research, developers of new medications must 
undertake FDA-mandated pre-marketing clinical trials using human subjects in three 
phases (7). In Phase I testing, researchers administer the new drug to a small group of 
volunteer subjects, generally between 20 and 80 people.  This initial testing determines 
the metabolism and pharmacologic action of the drug in humans, determines a safe 
dosage range, and identifies side effects associated with different dosages.  Phase I trials 
may include healthy individuals or patients with specific diseases.  In Phase II, 
researchers test the drug in a controlled trial on a somewhat larger group, usually between 
100 and 300 volunteers.  This phase studies the effectiveness of the drug in treating 
patients with one or more targeted conditions. Phase II also further evaluates safety and 
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determines common side effects.  A drug still promising after the first two phases 
undergoes Phase III trials. These include both controlled and uncontrolled studies 
typically enrolling 1000-3000 individuals. Phase III trials determine the overall risk-
benefit relationship for the new drug in treating a particular condition. 
 
 
 
 
Figure 1. Illustration of drug effects. We define a ―single drug ingredient‖ AE as those 
effects shaded in blue.  Arrows represent a ―may lead to‖ relationship. 
 
Some AEs do not arise in pre-market clinical trials for a variety of reasons (1).  
First, such clinical trials are relatively small (typically fewer than 3000 people), so they 
cannot detect rare side effects that occur in fewer than 1 in 10,000 patients. Upon 
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reaching the market, hundreds of thousands, or even millions, of people might use a new 
drug (3).  Second, inclusion criteria for FDA pre-marketing trials are often restrictive in 
terms of age, race, gender, and health status.  While necessary for accurate testing, a 
small, uniform population sample is unlikely to mimic the diverse spectrum of 
individuals who will eventually use the drug.  Additionally, controlled trials rarely 
emulate the exact conditions of medication use by the public at large. Pre-marketing trials 
cannot and do not fully explore effects of comorbid conditions, ranges of dosing, duration 
of administration, and interactions with other medications taken simultaneously.  
Unfortunately, this means that many medication AEs only appear after a large number of 
people have taken a drug over much longer periods of time than typical durations of pre-
marketing trials (2; 3). 
 
Examples of AEs discovered in post-marketing surveillance 
Rofecoxib (Vioxx), a COX-2 selective nonsteroidal anti-inflammatory drug 
(NSAID), was marketed by Merck to treat arthritis, acute pain in adults, and 
dysmenorrhea (8).  The FDA approved the sale of rofecoxib on May 21, 1999, and it 
became one of the best-selling prescription drugs worldwide. On September 30, 2004, 
after over 80 million people had taken the medication, Merck voluntarily withdrew the 
drug because of an increased risk of myocardial infarction (MI) and stroke that only 
appeared after 18 months of use of the medication (9).  Rofecoxib is no longer sold in the 
United States, but was available for over 5 years before these serious effects were 
discovered.  Valdecoxib (Bextra), another COX-2 NSAID, was also withdrawn from the 
market due to an increased risk of heart attack and stroke.  Due to these problems, the 
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FDA warns against the use of Celecoxib (Celebrex), another popular COX-2 NSAID, by 
patients at risk of heart disease, but there is at best contradictory evidence that it is 
associated with similar side effects. 
Rosiglitazone (Avandia) is a thiazolidinedione class drug that was widely used in 
the treatment of Type II diabetes.  The drug was approved by the FDA in 1999 and by 
2006 had sales of approximately $2.2 billion (10).  In 2007, an analysis published in the 
New England Journal of Medicine (NEJM) showed that rosiglitazone use increased the 
risk of MI and other adverse cardiovascular effects (11).  Despite some criticism of the 
NEJM study, and subsequent studies that provided mixed results, public confidence in, 
and sales of rosiglitazone dropped rapidly(12).  Three years after the NEJM study, on 
September 23, 2010, the European Medicines Agency (EMA) removed the drug from the 
European market and the FDA imposed significant restrictions on its use in the United 
States (13; 14).  While the NEJM study eventually discovered these AEs, the question 
remains whether information was available earlier that might have led to a more timely 
detection.  Another anti-diabetic drug in the thiazolidinedione class, pioglitazone (Actos), 
has a lower risk for MI than rosiglitazone, but was linked to increased risk of bladder 
cancer in 2011 after four years on the market.  As a result, France suspended the sale of 
pioglitazone, and the FDA has issued a warning that it should not be used in patients with 
a history of bladder cancer (15). 
The HMG-CoA reductase inhibitors (commonly known as statins) have been 
available in the U.S. since the 1980s.  This class includes the frequently prescribed drugs 
simvastatin (Zocor), atorvastatin (Lipitor), and rosuvastatin (Crestor).  More than 20 
million Americans currently take statins to lower their cholesterol levels (16).  On 
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February 28, 2012, the FDA announced that statin users have a dose-related increased 
risk for memory loss and for developing type II diabetes mellitus (17).  Using a 
conservative estimate that 1/200 patients treated with higher doses of the statins develop 
diabetes, suggests that up to 100,00 new statin-induced cases of diabetes would occur in 
the US alone (16). 
Finally, in recent news, on April 11, 2012, Johnson and Johnson was ordered to 
pay $1.2 billion in fines on charges that they minimized or concealed the dangers 
associated with the drug risperidone (18).  Risperidone is an anti-psychotic drug used to 
treat schizophrenia, bipolar disorder and behavior problems in teenagers and children 
with autism.  The adverse effects that were allegedly minimized or withheld include 
weight gain, increased risk of diabetes, and stroke. 
 
Prevalence of ADRs/AEs 
Studies have shown a surprisingly high prevalence of adverse drug reactions AEs 
and ADRs, in terms of both generic effects, such as allergic reactions, and medication-
specific pharmacological effects.  In 2004, a British study of 20,000 inpatients showed 
that 6.5% of admissions were associated with ADRs.  The ADR directly led to the 
admission in 80% of those cases (19).  A 2008 systematic review of 25 studies involving 
over 100,000 patients found that approximately 5.3% of hospital admissions were 
associated with ADRs. The ADR rate was higher in elderly patients, who more 
commonly receive multiple medications (20).  In 2010, a study of patients admitted to a 
1250-bed hospital in Dordrecht, The Netherlands, found that 19% to 29% of admissions 
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to the Departments of Internal Medicine, Cardiology, and Pulmonology were due to 
ADRs (21).  Adverse effects are a serious threat to patient safety.   
The withdrawal of drugs such as rofecoxib and rosiglitazone, as well as improved 
warnings for pioglitazone and the statins, illustrates that FDA monitoring can eventually 
detect dangerous AEs in the market. Nevertheless, the key question remains whether one 
could detect such important and unanticipated AEs sooner after a drug reaches the 
marketplace (1). 
 
Pharmacovigilance & Post-marketing surveillance 
The science of pharmacovigilance comprises detection, assessment, 
understanding, and prevention of AEs (22), including AEs at both normal and excessive 
doses.  Concerted and coordinated pharmacovigilance efforts began in the 1960s, 
including those of the World Health Organization (WHO) and the FDA. These followed 
the widespread, highly publicized, and tragic side effects of thalidomide administration 
during pregnancy.  Pharmacovigilance includes pre-marketing risk assessment of newly 
developed drugs, ongoing risk minimization, and post-marketing surveillance (23).  Post-
marketing surveillance is essential for identifying a medication’s AEs since it is unlikely 
that pre-marketing trials can be comprehensive enough to do so. 
In the 1960s, Spontaneous Reporting, the process of healthcare professionals 
reporting suspected ADRs to a national agency or to the drug manufacturer, became the 
standard method of gathering data for post-marketing surveillance.  Most countries 
collect such information in databases known as Spontaneous Reporting Systems (SRS).  
United States laws require drug manufacturers to submit reports of any suspected AEs to 
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the FDA.  In addition, hospitals, healthcare professionals, and patients can submit 
spontaneous reports to the FDA through a program called MEDWATCH (24). The 
current FDA AE database, the Adverse Event Reporting System (AERS) contains over 2 
million reports (24).  In addition to the national regulatory authorities (NRAs) of each 
European country, the EMA maintains an EU-wide spontaneous reporting database 
known as EudraVigilance (European Union Drug Regulating Authorities 
Pharmacovigilance) (25)(26). In 1968, the WHO set up the International Drug 
Monitoring Programme.  Today, it pools data from the spontaneous reporting systems of 
over 80 countries to assess post-marketing risk (27).  
SRS are well known for under-reporting, over-reporting, and duplicate reporting. 
Clinicians often under-report due to lack of time, education, and financial compensation, 
as well as fear of revealing medication errors, and a generally negative attitude towards 
reporting activity (25).  Additionally, the decision to report requires individual to make 
the connection between the event and the administration of the suspected drug; incidents 
that occur rarely, or seem disconnected from the drug administration for some reason, 
may go unreported. Examples of under-reporting include physicians not reporting effects 
that they do not consider significant or missing data in significant cases.  Examples of 
over-reporting might include physicians reporting known, well-understood, and common 
AEs.  Duplicate reports can be generated by physician or patient reports to the FDA 
followed by reports of the same incident by the drug manufacturer.  SRS also lack 
information on the number of individuals actually consuming a drug and contain limited 
temporal information (28). Additionally, there are significant differences in the reporting 
of serious versus non-serious AEs, as well as trends relating to time on the market and the 
10 
 
number of prescriptions written (29).  Oftentimes, these reports are focused on known 
AEs.   
The Medical Dictionary for Regulatory Activities (MedDRA) includes concepts 
such as diseases, diagnoses, signs, symptoms, therapeutic indications, and medication 
errors(30) that categorize AEs.  An international group of NRAs, including the FDA, 
EMA, WHO, and others, manages MedDRA.  Trained staff use MedDRA to process and 
encode spontaneous reports.  MedDRA has become the required or preferred terminology 
for reporting AEs throughout the world, facilitating collaborative data exchange and 
analysis (31).   
Traditionally, efforts to monitor spontaneous reporting databases have focused on 
review of individual case reports.  Newer methods facilitate analysis of aggregate data for 
purposes of detection and evaluation of what are known as ―signals‖ (32).  Signals are 
defined as threshold-based indicators that suggest a particular medication produces an 
AE, as detected by statistical, computational, or data-mining techniques in 
pharmacovigilance databases. Most methods use what is known as disproportionality 
analysis – that is, methods that measure the extent to which a given AE is 
disproportionally reported with a given drug (32).  These methods have been validated in 
drug safety research, but they are only exploratory; one cannot draw conclusions solely 
from disproportionality analysis or any other single method (33).  Definitive proof can 
only come from a convergence of experimental, clinical, and statistical research. 
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Signal Detection Methods and Examples 
One of the most popular disproportionality analysis methods is the Proportional 
Reporting Ratio (PRR). Developed in 2001 by researchers using the UK SRS, the PRR is 
analogous to the concept of epidemiology concept of proportional mortality ratios (PMR) 
(34) (35).  The PRR for a particular AE is defined as the ratio of the particular AE among 
all AEs for the given drug, divided by the ratio of the particular AE among all AEs for all 
drugs.  One major drawback for the PRR, however, is that it is ―numerator-based.‖  
When estimating the prevalence of an AE with a particular drug, the ―numerator‖ 
is the number of users experiencing an AE, while the ―denominator‖ is the total number 
of individuals using the drug (34).  Since the focus of a spontaneous report is on a user 
experiencing an AE, SRS do not contain information on the total number of users taking 
the drug in the population.  Therefore, most methods are numerator-based. 
One of the strengths of the PRR is that underreporting of adverse events should 
not influence the PRR, given that the AE in question is equally underreported as the 
aggregate of other AEs in the SRS.  Unfortunately, the PRR also suffers from the same 
weaknesses of the PMR.  The size of the numerator influences the size of the 
denominator and thus distorts the PRR; therefore a drug can appear to increase the risk of 
an AE solely because it reduces the risk of another AE (36).  The PRR is frequently used 
in the EMA’s EudraVigilance (37). 
Another common numerator-based method is the Reporting Odds Ratio (ROR). It 
is similar to the PRR, but it is computed by viewing the SRS database as a case-control 
study; unlike the PRR, the ROR excludes any cases from the denominator that are 
suspected of being related to exposure of the drug in question.  So unlike the PRR, the 
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ROR is an unbiased estimator of the risk ratio (36).  Researchers frequently use the ROR 
to analyze data from the FDA’s AERS (30). 
Other statistical measures include Pearson’s Chi-Square and the Poisson 
probability test.  The chi-square test is used as a test of independence between two 
variables – whether a patient was exposed to the drug and whether the patient suffered 
the adverse effect.  The Poisson distribution, often used to model rare events in large 
samples, is popular as well. Research has shown that methods such as the PRR, ROR, 
Poisson probability test, and the Chi-square test are broadly comparable when four or 
more cases per combination have been collected (38).  Correlation analysis, multivariate 
regression, and Bayesian logistic regression are used, as well.   
In addition to statistics, data mining methods have been used in post-marketing 
signal detection as well.  Bayesian Confidence Propagation Neural Networks (BCPNN), 
a form of Bayesian data mining, used ideas from Information Theory to calculate a 
quantity known as the information component (IC) for each possible drug-event 
combination in a database.  Signal detection is based upon this value and the time trend 
of the data (34).  It is one of the primary methods used by the WHO.  Empirical Bayes 
Screening (EBS), another Bayesian data mining technique, has been applied to the FDA’s 
AERS.  EBS ranks drug-event combinations according to how large the number of 
reports for a given combination is compared with what would be expected if the two were 
statistically independent (31).  Unlike BCPNN, which provides a stand-alone measure for 
each drug-event combination, EBS provides only an overall ranking of drug-even 
combinations.  A more thorough discussion on the strengths and weaknesses of many of 
these methods can be found in (33; 35; 36; 39). 
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Harpaz and Friedman at Columbia have done groundbreaking work in applying 
data-mining techniques to investigate drug interaction adverse effects – AEs that are 
caused by a specific combination of two or more drugs.  Using popular association rule 
mining techniques, they investigated associations in the FDA’s AERS between sets of 
drugs and sets of findings (40; 41).  Similarly, they later applied the biclustering 
paradigm to the AERS to identify drug groups that share a common set of AEs.  
Application of that information could allow researchers to gain insight into the etiology 
of AEs (42).  
As late as 2005, it was suggested that no major stakeholders had the goal of 
hypothesis-free examination of large databases in efforts to find new AEs (1).  While 
methods exist which attempt to compensate for the shortcoming of SRS (43), methods 
that focus on new data sources with fewer limitations must also be explored. 
 
Identifying AEs From EMR Data 
Spontaneous reporting databases once stood as the only systems that had the 
necessary data in machine-readable formats for large-scale AE signal detection.  
However, with the proliferation of EMRs, substantive drug and finding data now exists at 
most healthcare institutions, providing an important opportunity for post-marketing 
surveillance (44). 
In recent years, there have been several attempts to scan EMRs for AEs.  In 2001, 
Honigman, et al., (45) were able to identify known AEs in the ambulatory setting using 
diagnosis codes, allergy rules, computer event monitoring, and text searching.  These 
methods had a sensitivity of 58%, specificity of 88%, and a positive predictor value 
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(PPV) of 7.5%.  In 2003, Murff, et al., (46) searched free text discharge summaries for 
trigger words that indicated a possible adverse event.  The study achieved sensitivity, 
specificity, and PPV of 69%, 48%, and 52%, respectively.  In the 2004-2007 NIH-
sponsored TIME (Tools for Inpatient Monitoring Using Evidence) project, Miller and 
colleagues at Vanderbilt correlated inpatient laboratory test abnormalities with CPOE-
based medication orders to discover time dependencies of known AEs and attempt to find 
new AEs (47–49). In 2004, Field, et al., (50) examined multiple strategies for identifying 
AEs in older patients in ambulatory clinics, including manual review of clinician and 
administrative incident reports, electronic codes, and automated text searching of patient 
notes for known drug-AE combinations.  They found far more instances of AEs than 
were actually labeled in the records, suggesting that one should use multiple strategies to 
detect AEs in clinical notes.  In 2009, Hazlehurst, et al., (51) used NLP to detect AEs in 
clinical notes.  As part of the Vaccine Safety Datalink collaboration, researchers modified 
an existing NLP tool so that it could recognize possible general vaccine adverse events 
(VAEs), and specifically gastrointestinal-related VAEs.  The authors believed their 
reported sensitivity, specificity, and PPV (75%, 97%, and 89%, respectively) improved 
on previous work due to more sophisticated NLP methods. 
At Columbia, Friedman, Wang, and colleagues showed that NLP could 
effectively identify disease, symptom, and AE concepts in EHRs.  In 2008, they reported 
extracting diseases and related symptoms with a recall of 90% and precision of 92% from 
discharge summaries (52).  They also used NLP to extract disease-drug co-occurrence 
statistics discharge summaries, as well as from Medline articles (6).  Building on their 
previous work, Wang and Friedman were later able to use NLP to extract both disease-
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symptom and drug-AE pairs from clinical notes, filtering out sections of the note that are 
not directly related to patient experiences (such as ―family history‖) to improve precision 
and recall to 0.92 and 0.90 for disease-symptom pairs and 0.31 and 0.75 for drug-AE 
pairs (5).  In 2009, Wang & Friedman, et al., used NLP to identify drugs and findings in a 
collection of 25,074 discharge summaries.  Using co-occurrence statistics, they found 
correlations between seven drugs/drug classes and their known AEs.  They had a recall of 
0.75 and a precision of 0.31 for the known AEs, and based upon dates of the discharge 
summaries, showed that novel AEs would likely have been detected using their 
methodology (4).   
The FDA’s recent Sentinel Initiative aims to ―create a linked, sustainable system 
that will draw on existing automated healthcare data from multiple sources to actively 
monitor the safety of medical products continuously and in real time‖ (53).  Sentinel will 
monitor drug safety and, eventually, all FDA-regulated products.  This will include data 
mining of healthcare information stakeholders (i.e., insurance companies and hospitals).  
After a successful pilot program, the FDA is developing and implementing Sentinel in 
stages.  Key project areas include: evaluation of potential data sources; evaluation of 
existing methods of signal detection; engagement of patients, consumers, and healthcare 
professionals; evaluation of potential database models; and the evaluation of privacy 
regulations. 
 
Drug Indication and Adverse Effect Information Sources 
When analyzing the co-occurrences among drugs and findings in EHRs, 
correlations (signals) will be identified not only between drugs and novel AEs, but also 
16 
 
between drugs and indications and drugs and known AEs.  In order to discover new AEs, 
one must distinguish these unknown signals from those that are already understood.  
Several resources exist that catalog drug indications and adverse effects.  DailyMed is a 
NLM-operated website that makes FDA-approved prescription drug labels available to 
the public (54).  Commercial resources such as Micromedex, First Databank (FDB), 
UpToDate, and many others provide drug information including treatments and dose 
amounts for a given conditions or AEs for specific medications (55–57).   
Despite this wide variety of drug knowledge resources, there is no definitive 
source with all information in a structured format.  In 2010, Wang, et al., attempted to 
compile drug indication information from a combination of sources: the FDA AERS, 
SemMed – a database generated from NLP on MEDLINE abstracts, and the National 
Drug File-Reference Terminology (NDF-RT) (58).  In 2011, Li, et al., applied 
information from Micromedex, NDF-RT, and the AERS to identify the reasons for 
prescriptions for 20 drugs mentioned in EHR discharge summaries.  They achieved 62% 
sensitivity, 93.9% specificity, 90% precision, and an F-measure of 73.9% (59). 
 
Summary 
As proposed by the MOMENT project (47–49) and similar to Wang, et al. (4), we 
used NLP on narrative clinical reports to identify co-occurrence of drugs and findings, 
and to study the feasibility of using this data for identifying novel adverse effects.  Unlike 
Wang, et al., the current project uses History and Physical exam (H&P) notes instead of 
discharge summaries, and captures data from a much larger corpus of notes.  While 
discharge summaries may contain major findings, therapies, and diseases, we believe 
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H&Ps provide a deeper and richer picture of patient findings and symptoms prior to what 
happened during a hospital admission. Since we are interested in discovering AEs related 
to prescription medications that the patient is taking outside of the hospital, we believe it 
is better to capture medications and symptoms at time of admission (when H&Ps are 
recorded).  Similar to (5), we used clinical note section header data to restrict the sections 
from which we mine concepts, eliminating potential ―false positive‖ terms from sections 
such as ―Plan‖ and ―Family Medical History.‖  Additionally, we developed an automated 
methodology to generate a knowledge base of known drug-finding pairs, and to use this 
knowledge to identify known drug-finding pairs from our results.  We did not intend to 
discover novel adverse effects at this stage of research, but we hoped to re-identify AEs 
that were discovered using post-marketing surveillance in the past and explore the 
potential for using this approach to discover novel associations in the future. 
In summary, previous studies have examined the co-occurrence of drug and 
findings concepts using NLP, but others often performed their research on discharge 
summaries, which could confound drug effects prior to hospital admission with drug 
effects that occurred post admission.  H&Ps contain a richer set of findings and 
symptoms because, while discharge summaries catalog the course of treatment in-
hospital, H&Ps attempt to describe the patient’s health more fully.  Additionally, the 
Vanderbilt Synthetic Derivative provided us with the opportunity to use far more records 
than most previous studies, potentially allowing us to identify rare effects.  Finally, 
through the creation and application of a drug-finding evidence base, we automatically 
identified known indications and adverse effects from the drug-finding correlations 
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discovered in the corpus of H&P notes, improving our ability to identify previously 
unknown correlations. 
 
Project Specific Tools 
 
Unified Medical Language System 
The Unified Medical Language System (UMLS) is a collection of controlled 
vocabularies and ontologies in the biomedical sciences and healthcare.  The UMLS is 
primarily composed of three knowledge sources (databases) – the Metathesaurus – 
database of vocabularies that contains information about biomedical and health-related 
concepts; the Semantic Network – information on the semantic types of and relationships 
between concepts in the Metathesaurus; and the SPECIALIST Lexicon – a source of 
lexical information for use with NLP tools (60–63). 
We used UMLS version 2009AA throughout this project because it was the 
version of UMLS being currently used by our tools the KnowledgeMap Concept 
Identifier and MedEx (see below).  We made significant use of the semantic types, 
UMLS Concept Unique Identifiers (CUIs), the UMLS co-occurring concepts table 
(MRCOC), and two drug vocabularies included in the UMLS – RxNorm and NDF-RT. 
 
KnowledgeMap Concept Identifier 
The KnowledgeMap Concept Identifier (KMCI) is a natural language processing 
(NLP) tool developed at Vanderbilt by Denny, Miller, Spickard, et al.  Originally 
developed for use in medical education (64), it has been extended for use in clinical 
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research.  KMCI is an NLP tool that indexes Unified Medical Language System (UMLS) 
concepts that occur in an input document.  KMCI uses UMLS-derived resources, along 
with locally developed and publically available components, for word and term 
normalization, language processing, and concept identification.  When candidate 
concepts have multiple UMLS matches, KMCI resolves ambiguous concepts using 
previously matched concepts and document context. 
KnowledgeMap is used extensively at Vanderbilt for both medical education and 
research.  KMCI is used to index concepts in the medical school curriculum to allow 
students easy access to information from course documents on a particular topic (64).  
KMCI has been used to extract EKG findings from clinical reports and correlate them 
with patient medication administration records in order to identify patients with 
prolonged QT intervals (65).  KMCI was also used to recognize clinical text descriptions 
of colonoscopy screening events, status of the procedures’ completion, and the dates the 
procedure was performed (66).  It was later extended to better identify colorectal cancer 
in EMRs by recognizing three additional tests – flexible sigmoidoscopy, fecal occult 
blood testing, and double contrast barium enema – and determining whether testing was 
planned or completed and to estimate the date of completed tests (67).  Another research 
project used KMCI to extract noun phrases from article titles in the American Journal of 
Epidemiology and, using heuristic rules, identify terms that contained epidemiologic 
exposure (68).  KMCI has also been used for phenotype identification algorithms  (69; 
70). 
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SecTag 
SecTag is another Vanderbilt-developed NLP tool used in clinical research.  
Developed by Denny, Miller, Spickard, et al., SecTag is used to identify section headers 
in clinical notes.  The SecTag algorithm uses a locally developed lexicon of ―clinical note 
section header‖ terms and heuristics to identify sections in H&P notes, such as ―History 
of Present Illness,‖ ―Medications,‖ or ―Family Medical History.‖  SecTag identifies not 
only major headings, such as ―Cardiovascular Exam,‖ but also subheadings within 
sections, such as ―Cardiac Auscultation.‖  In some instances, SecTag can also detect 
implied section headers, such as those for ―Chief Complaint,‖ using a modified Naïve 
Bayes algorithm combined with terminology-based rules.  An evaluation of SecTag on 
319 randomly select EMR H&P notes found 16,036 sections.  Physician reviewers agreed 
with SecTag for 15,329 tags and identified 160 sections that were not recognized by the 
algorithm.  The recall and precision of the SecTag algorithm were 99.0% and 95.6% for 
all sections, 98.6% and 96.2% for major sections, and 96.6% and 86.8% for unlabeled 
sections (71). 
 
MedEx 
MedEx is a Vanderbilt-developed NLP tool for extracting medications and 
medication-related information from natural language clinical notes. Developed by Xu, 
Denny, et al., MedEx extracts medication name, both generic and brand names, as well as 
other strength, dose, route, frequency, form, dose amount, intake time, duration, dispense 
amount, refill, and necessity, if they are present.  Tested on discharge summaries, MedEx 
was shown to be very reliable in extracting not only drug names (F-measure 93.2%), but 
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also related information such as strength, route, and frequency, with F-measures of 
94.5%, 93.9%, and 96.0% respectively (72).  MedEx was later combined with other NLP 
tools, including SecTag, to participate in the 2009 i2b2 NLP challenge, placing second 
overall (73).  It achieved an overall F-measure of 0.821 for exact matching with a 
precision of 0.839 and recall of 0.803 and an F-measure 0.822 for inexact matching 
(precision 0.866 and recall 0.782) (74).   
MedEx has been used in studies to calculate the daily dose of drugs mentioned in 
clinical text.  Specifically, MedEx was extended to normalize dose-related findings and 
calculate daily doses of the medication tacrolimus.  Precision was greater than 0.90 and 
recall greater than 0.81 (75).  MedEx was further extended to calculate weekly doses of 
the drug warfarin in another study.  It determined patients’ weekly doses with 99.7% 
recall, 90.8% precision, and 93.8% accuracy (76).  MedEx is also extensively used at 
Vanderbilt to identify medications present in the Synthetic Derivative (SD) – the de-
identified version of the Vanderbilt EMR used for research.  
 
Vanderbilt Synthetic Derivative 
The Synthetic Derivative (SD) is a comprehensive database containing nearly all 
clinical information present in the Vanderbilt ―Star‖ EMR system (77).  This includes 
laboratory values, billing codes, imaging and pathology reports, and clinical narratives 
from both the inpatient and outpatient setting.  The SD is a de-identified resource; it is 
stripped of personal identifiers such as names, places, and addresses, dates are shifted by 
up to one year backward (consistent within each record but different across records), and 
medical record numbers are hashed to a new value consistent for each record.  It is 
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updated nightly with new information from Star.  The SD can be used as a stand-alone 
resource for clinical research, or as part of the BioVU program, in combination with 
genetic samples for phenome-genome analysis. 
 
UMLS Co-Occurring Concepts (MRCOC) 
The MRCOC contains aggregations of co-occurrences of concepts from multiple 
data sources, including MEDLINE (Medical Literature Analysis and Retrieval System 
Online), the AI/RHEUM Knowledge Base, and Canonical Clinical Problem Statement 
System (CCPSS) (78).  AI/RHEUM contains co-occurrence of diseases and findings; 
CCPSS contains problem-problem co-occurrences extracted from patient records.  Since 
we are attempting to classify drug-finding co-occurrences, we focused solely on the 
MEDLINE data. 
The MEDLINE co-occurrence data in MRCOC was compiled from the MeSH 
(Medical Subject Headings) concepts designated as main topics of a given indexed 
journal article.  Counts exist for the frequencies with which the first concept is qualified 
with MeSH qualifiers when it appears with the second concept.  Separate counts and 
subheadings are provided for each direction of the relationship; that is, MRCOC gives the 
qualifying MeSH terms for concept one when it appears with concept two, as well as the 
qualifiers for concept two when it appears with concept one.  MRCOC contains separate 
counts for recent MEDLINE entries, designated as MED and including entries from the 5 
years prior to release (2003 – 2008), as well as entries from a preceding 5-year bloc, 
designated MBD (1998 - 2002) (79). 
 
23 
 
RxNorm 
RxNorm is a standardized nomenclature of drugs and drug delivery devices 
developed by the National Library of Medicine (80).  With RxNorm, medications are 
represented as ―clinical drugs.‖  Each clinical drug is defined by one or more ingredients, 
possible strengths, and dose forms.  Since drug concepts are formed from these 
constituent pieces, clinical drugs can be mapped back to other doses or forms, and more 
importantly, generic ingredients.  These mappings allow a user to link a brand name or 
dose-form drug with its generic ingredient concept(s) (81).  RxNorm is included as part 
of the UMLS.  We used the RxNorm version included in the UMLS2009AA release 
throughout this project. 
 
National Drug File – Reference Terminology 
The National Drug File – Reference Terminology (NDF-RT) is produced by the 
U.S. Department of Veterans Affairs Veterans Health Administration (VHA) since 2002 
(82).  It is an extension of the VHA National Drug File.  The NDF-RT organizes the list 
of drugs into a formal representation used for modeling drug characteristics.  Among 
other things, this includes ingredients, dose form, physiologic effect, mechanism of 
action, related diseases, and 25 distinct relationship types between concepts.  Information 
exists for approximately 80,000 orderable compositions associated with 4000 active 
ingredients (83).  Among other features, the NDF-RT contains 25 distinct relationship 
types between concepts (81; 84).  Both RxNorm and NDF-RT contain mappings among 
drug concepts. These mappings allow a user to link a brand name or dose-form drugs 
with its generic ingredient concept (81).   
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The NDF-RT is updated regularly and new versions are released every six weeks.  
Each new release of the UMLS Metathesaurus contains the most recent version of the 
NDF-RT, as a part of RxNorm.  We used version NDFRT_2008_03_11, the version 
contained in the UMLS 2009AA release used throughout this project. 
 
Structured Product Labels 
The Food and Drug Administration’s Structured Product Labeling (SPL) is a 
XML (Extensible Markup Language) document standard for the labeling of human 
prescription drugs in the United States.  Structured Product Labels contain information 
such as product names, generic names, ingredients, strengths, dosages, dose forms, and 
route of administration.  In addition, they contain the full product labels from drugs sold 
in the United States (85).  While the document is encoded using XML, the content of the 
sections is in unstructured natural language. 
 
SIDER Side Effect Resource 
The SIDER Side Effect Resource is a database that connects 925 drugs to 1450 
side effect terms (86).  The information contained in SIDER was extracted from the FDA 
SPLs using text-mining methods.  The indication and adverse effects used by SIDER are 
from the COSTART (Coding Symbols for Thesaurus of Adverse Reaction Terms) (87) 
vocabulary, and are thus already in the UMLS with CUI representation.  Drugs in the 
SIDER database are identified using a STITCH ID from PubChem (88). SIDER is 
available freely on the web and for download (89). 
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CHAPTER III 
 
DRUG INDICATIONS AND ADVERSE EFFECTS EVIDENCE BASE 
Overview 
We constructed the Drug Indications and Adverse Effects Evidence Base (DEB, 
for Drug Evidence Base) to enable an automated system to identify potential explanations 
for why specific drug-finding pairs appear in clinical notes.  To build the drug evidence 
base, we used information from the UMLS Co-Occurrence of Concepts (MRCOC), the 
National Drug File-Reference Terminology (NDF-RT), and the Food and Drug 
Administration’s Structured Product Labels (SPL) for human prescription drugs.  Based 
on data extracted from these resources, we algorithmically classified a drug-finding pair 
as an adverse effect (AE) – that is, the drug causes the finding – or an indication (IND) – 
the drug treats or prevents the finding.  
The development of the DEB involved operational definition of a drug-finding 
pair; extraction of the relevant information from each of the knowledge sources; and 
reconciliation of this information into the evidence base.  We compared the evidence base 
to the existing widely-used SIDER Side-Effect Resource to evaluate the DEB’s 
comprehensiveness and accuracy. 
 
Materials 
This work was performed on a MacBook Pro with a 2.8 GHz Intel Core 2 Duo 
processor and 8 GB of RAM and a Linux server with eight 2.0 GHz Intel Xeon cores and 
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16 GB RAM.  All data processing scripts were written in Perl. 5.10.0.  The project used 
MySQL version 5.5.16. 
 
Methods 
 
Definition of Drug-Finding Pairs 
Throughout this work, we defined a drug-finding pair as the co-occurrence of a 
particular Unified Medical Language System (UMLS) drug identifier (i.e., its name) and 
a particular UMLS clinical finding name that appeared together in a relevant clinical 
resource (e.g., SPL, NDF-RT, or a patient’s clinical note).  A drug refers to a single-
ingredient medication.  A finding can describe indications for drug therapy (e.g., a 
disease treated or prevented by the drug) or adverse effects of therapy (e.g., a physical 
examination finding, such as maculopapular rash). We designated all concepts using 
specific UMLS Concept Unique Identifiers (CUIs).  We did not constrain concept origins 
to any specific UMLS source vocabularies.  We used the UMLS 2009AA release because 
project tools, KMCI and MedEx, used that version. 
We operationally constrained our definition of ―drug‖ to include a UMLS concept 
that had at least one of the following UMLS semantic types:  
 Antibiotic 
 Pharmacologic Substance 
 Clinical Drug 
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Based on review of several hundred de-identified patient charts by an experienced 
project clinician (RAM), we operationally constrained our definition of ―finding‖ to 
UMLS concepts having at least one of the following semantic types:  
 Anatomical Abnormality 
 Injury or Poisoning 
 Congenital Abnormality 
 Finding 
 Sign or Symptom 
 Acquired Abnormality 
 Clinical Attribute 
 Disease or Syndrome 
 Mental or Behavioral Dysfunction 
 Neoplastic Process 
 Pathologic Function 
 
Extracting Pairs from UMLS Co-Occurring Concepts (MRCOC) 
The ―MRCOC component‖ of the DEB was derived from co-occurring concepts 
from articles indexed in MEDLINE (using both MED and MBD intervals, discussed 
above).  To do so, we extracted from the UMLS MRCOC table those drug-finding pairs 
that potentially denoted an AE or IND. Each entry in MRCOC consists of two concepts, 
their source information, the number of co-occurrences in the literature during a specified 
time period, and the MeSH subheadings qualifying the relationship between the two 
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concepts as they appeared in the literature.  The MRCOC table contains separate entries 
for each direction of the relationship between two distinct concepts (see Figure 2).  
Procedurally, we extracted all MRCOC entries in which the first concept (cui1 in 
Figure 2) met our definition as a drug and the second concept (cui2 in Figure 2) qualified 
as a finding (per definitions above), or vice versa. Next, we combined entries from the 
UMLS time intervals MED and MBD entries (mentioned above, shown below in 
―source‖ column in Figure 2) and summed the co-occurrence counts (―count‖ column in 
Figure 2) and the individual subheading counts (rightmost column in Figure 2).  We only 
retained subheading information for the following relevant MeSH subheadings: AE – 
Adverse Effect; DT – Drug Therapy; ET – Etiology; and TU – Therapeutic Use.  Lastly, 
to ensure well-established relationships for a given pair, we discarded drug-finding pairs 
with an overall co-occurrence count less than 4. 
As illustrated in Figure 2, MeSH subheadings in the rightmost column of the 
MRCOC table only apply to the first of the paired two concepts when they appear 
together.  We utilized the MRCOC subheading information to infer whether the 
relationship between drug and finding was most likely IND or AE.  When the subheading 
TU qualifies the drug concept of the drug-finding pair, this suggests the finding is an IND 
for the ―therapeutic use‖ of the drug. When the subheading DT qualifies the finding 
concept of the drug-finding pair, this further supports that the finding was an IND for the 
―drug therapy‖.  When the subheading AE (―adverse effects‖) qualifies the drug concept 
of the drug-finding pair, this directly suggests that the finding was an AE.  Similarly, 
when the subheading ET qualifies the finding concept of the drug-finding pair, this 
indicates that administration of the drug may have played a role in the etiology of the 
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finding (i.e., the finding was an AE).  Thus, the combination of the subheadings is 
important; drug/TU+finding and drug+finding/DT implies an indication and 
drug/AE+finding and drug+finding/ET implies an adverse effect. Nevertheless, the actual 
indexing of articles in the literature (which may describe concurrent use of multiple drugs 
for multiple conditions with multiple possible interrelationships) can produce conflicting 
information. We describe how we addressed such conflicts below. 
We stored the ―MRCOC component‖ of the DEB in a temporary MySQL table 
before combining this information with the other DEB sources (see below).  For each 
MRCOC drug-finding pair, the temporary table contained two entries, one for each 
direction of the relationship, along with subheadings and co-occurrence counts, as 
described above and illustrated in Figure 2.  
 
UMLS MRCOC Table 
 
         |          |         |       | mesh subheadings of cui2 when it 
  cui1   |  cui2    | source  | count | appears with cui1 
+--------+----------+---------+-------+-------------------------------------+ 
 C0043031| C0038454 |   MBD   |   91  | TU=74,AD=22,AE=20,CT=6,EC=3... 
 C0043031| C0038454 |   MED   |  121  | TU=89,AD=41,AE=29,CT=4,EC=4... 
... 
 C0038454| C0043031 |   MBD   |   91  | PC=78,ET=42,EP=10,DT=9,MO=6... 
 C0038454| C0043031 |   MED   |  121  | PC=100,ET=55,DT=21,EP=20,MO=6... 
 
Combining sources and discarding extra subheadings... 
 
 C0043031| C0038454 | MED+MBD |  212  | TU=163,AE=49 
 C0038454| C0043031 | MED+MBD |  212  | ET=97,DT=30 
 
Figure 2.  Sample MRCOC data for Warfarin (C0043031) and Stroke (C0038454) 
 
 
Extracting Pairs from National Drug File Reference Terminology (NDF-RT) 
To create the ―NDF-RT component‖ of the DEB, we extracted drug-finding pairs 
from the NDF-RT information included in the UMLS MRREL table. As indicated in 
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Figure 3, we extracted all MRREL entries from NDF-RT that contained a drug concept 
and a finding concept that also had one of the following NDF-RT relationships: ―has 
physiologic effect‖ and ―induces‖ (indicating a potential AE), and ―may prevent‖ and 
―may treat‖ (indicating a likely IND).  The final form of the data extracted from NDF-RT 
included, for each entry, a drug CUI, a finding CUI, and all of the relevant relationships 
that appear between the two CUIs. 
 
 
  drugCUI | findingCUI | relationship(s) 
+---------+------------+---------+-------------------------------------+ 
  C2267047|  C0035235  | may_prevent,may_treat  
  C1096766|  C0041657  | induces  
  C0913469|  C1371635  | has_physiologic_effect  
  C2587204|  C0040136  | may_treat  
 ... 
 
Figure 3. Sample rows from the temporary table for the NDF-RT component.  
 
 
Extracting Pairs from FDA Structured Product Labels (SPLs) 
To create the ―SPL component‖ of the DEB, we extracted drug-finding pairs 
using NLP of the FDA’s product labels for prescription drugs. 
We downloaded all available human prescription drug product labels from 
DailyMed (54), as well as the SPL Downloadable Data Elements file (90). This file acts 
as in index for the SPLs, containing information such as National Drug Code (NDC), 
proprietary name, ingredient(s), product type, marketing category, and a link to the 
appropriate SPL files. Based on NDC, this contained information on 56,854 drugs 
associated with approximately 2400 unique sets of ingredients, often containing more 
than one active ingredient.   
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Using the index, we selected all ingredient and proprietary names for drugs 
containing a single active ingredient and with a ―product type‖ indicating the name 
applied to a Human Prescription Drug. We then automated a process whereby these 
ingredients were mapped to CUIs by exact match with UMLS strings of drug concepts 
available in the MRCONSO table of the UMLS Metathesaurus.  We manually reviewed 
these matches to confirm accuracy and correct any mismatches or unmatched ingredients 
where possible.  
For every drug that we were able to match to a CUI, we then parsed the respective 
SPL. Using the XML structure, we extracted the Adverse Reactions Section (section 
34084-4) and the Indications and Usage Section (section 34067-9) when they were 
present (91).  We then used the Knowledge Map Concept Identifier (KMCI) to extract all 
of the finding concepts in each section for each label. 
Since the SPLs contain entries for every drug marketed in the US, there are many 
duplicates. For example, there is a label for every package quantity, dose form, and brand 
name of acetaminophen.  Therefore, a single CUI often mapped to many different SPLs.   
For each SPL, we extracted a set of all unique finding concepts identified in the 
AE section, another of all unique finding concepts in the IND section.  This data was then 
transformed into a table of drug-finding pairs by linking the drug CUI with the CUI of 
every distinct concept identified in the Adverse Reactions Section (classified as an AE) 
and the CUI of every distinct concept identified in the Indications and Usage Section 
(classified as an IND).   
The final form of the data we extracted from the SPLs includes, for each entry, a 
drug CUI, a finding CUI, whether or not this was mentioned as an AE, and whether or 
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not this was mentioned as an IND (see Figure 4).  It is possible for a concept to appear as 
both an AE and an IND.  We discuss this issue in the following section on construction of 
the final combined evidence base.  
 
 
  drugCUI | findingCUI | AE | IND  
+---------+------------+----+-----+ 
  C0059985|  C1514463  | AE |      
  C0059985|  C1517205  | AE | 
  C0060135|  C0002874  | AE | IND 
  C0248719|  C0262926  |    | IND 
  C0249529|  C0018418  | AE | 
 ... 
 
Figure 4. Sample rows from the temporary table for the SPL component.  
 
 
Mapping to Uniform Drug Concepts 
A wide variety of medication-related identifiers from the three DEB knowledge 
sources met our UMLS-semantic-type-based definition of a drug.  For instance, 
C0000970 – Acetaminophen, C0699142 – Tylenol, and C1640784 – Tylenol 160 mg 
were all unique UMLS CUIs that appeared in the DEB knowledge sources, and might 
also appear in patient notes.  While these CUIs all represent the same drug ingredient, 
they all correspond to different UMLS concepts. The first is a generic drug, the second is 
a brand name drug, and the third is a dispensable form of the drug that includes a specific 
dose.  The DEB requires, whenever possible, that a single identifier/name be assigned to 
all single-component drugs that involve the same generic ingredient.  To combine and 
condense the DEB drug names from multiple sources, we mapped each identified drug 
CUI to a drug generic ingredient using the relationships in MRREL, predominantly using 
mappings from RxNorm. In particular, we used the relationships ―ingredient of‖ and ―has 
ingredient‖ to map dose forms of a drug to the drug ingredient only (C1640784 – Tylenol 
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160 MG to C0699142 – Tylenol).  We also used the ―has tradename‖ and ―tradename of‖ 
relationships to map a brand name drug back to its generic ingredient name (C0699142 – 
Tylenol to C0000970 – Acetaminophen). We mapped all specific instances of each drug 
term to its generic ingredient, whenever mappings existed. 
 
Integrating Source Information into Combined Evidence Base 
We combined the data extracted from MRCOC, NDF-RT, and SPL components 
of the DEB into a single DEB table. This table contained a single entry for each generic-
drug--finding pair. To combine data regarding whether the pair comprised an IND or an 
AE, we developed a scoring system that assigned weights to the information from the 
three disparate sources. We created scores indicating the level of support for a pair being 
an AE versus an IND (the INDscore and the AEscore). We ranked the three component 
sources based on our own interpretation of their authoritativeness to determine the 
maximum number of points each could contribute to the overall score.   
We rated the NDF-RT highest because it is a manually curated, trusted knowledge 
source and because the NDF-RT relationships that we used state directly whether a drug-
finding pairing represents an IND or an AE. The NDF-RT component contributed 10 
points to the AEscore if a relationship indicating an AE was present, and 10 points to the 
INDscore if a relationship indicating an IND was present.  If NDF-RT indicated that both 
an AE and IND relationship were present, we added 10 points to each score.   
We rated the MRCOC component as second most authoritative because it was 
based on NLM indexers reviewing articles published in the peer-reviewed literature.  It 
could contribute a maximum of 10 points, but the exact score was based upon the fraction 
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of co-occurrences that indicated either AE or IND.   More specifically, if there were X 
subheading counts that supported an AE determination, Y subheading counts that 
supported an IND determination, and N total co-occurrences, (X/N)*10 points were 
added to the AEscore and (Y/N)*10 points were added to the INDscore. 
We gave the SPL component the lowest weighted proportion of the overall score, 
not because of the authoritativeness of SPL per se, but because extraction of information 
via NLP was deemed to be potentially unreliable. This process involved the least amount 
of manual review – concepts were extracted automatically using NLP, unlike the 
structured expert-derived NDF-RT or the structured manual coding of MeSH terms.  The 
SPL component contributed a maximum of 5 points to the scores.  If a drug-finding pair 
was designated only as an AE or an IND in SPL, 5 points was added to appropriate DEB 
score.  If, however, there was contradictory evidence – that is, a finding appeared in both 
the Indications section and Adverse Effects section of the SPL, we added 2 points to 
AEscore and 4 points to INDscore.  We assigned the slight advantage to IND because we 
observed that mentions of indications often appeared in the text of the Adverse Effects 
sections of the SPL, as in ―When treating for the indication XYZ, adverse effects might 
include…‖. Our NLP processing typically would label XYZ as an IND and an AE in such 
circumstances.  Therefore, if a concept appeared in both SPL sections, we assigned a 
higher value to IND. 
Finally, we algorithmically compared the overall AEscore and INDscore as 
determined by the combined three sources, and used the larger of the two scores to 
determine the final DEB classification of a drug-finding pair.  In the case of a tie, we 
assigned IND because we observed that when there was evidence for a drug being both 
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an IND and an AE, it was often when a treatment when withdrawn, might exacerbate the 
treated condition, such as when withdrawal of clonidine exacerbates the hypertension it 
was previously treating.  The DEB only classifies a drug-finding pair as AE or IND; there 
is no ―both.‖  A large difference between the AE score and IND score implies higher 
certainly, whereas very similar scores imply less certainty.   
 
 
  drugCUI | findingCUI | Sources         |INDscore |AEscore|Determination 
+---------+------------+-----------------+---------+-------+-------------+ 
  C0020740|  C0029408  | mrcoc,ndfrt,spl | 25.00   |  5.00 | IND 
  C0020740|  C0029882  | mrcoc           |  5.00   |  5.00 | IND 
  C0020740|  C0038358  | mrcoc           |  4.29   |  5.71 | AE 
  C0020740|  C0038454  | mrcoc,spl       |  3.33   | 11.67 | AE 
  C0020740|  C0021368  | mrcoc,ndfrt     | 18.00   |  0.00 | IND 
 ...  
 
Figure 5. Sample rows from the combined DEB for Ibuprofen (C0020740) and 
Degenerative Polyarthritis (C0029408), Otitis Media (C0029882), Gastric Ulcer 
(C0038358), Cerebrovascular Accident (C0038454), and Inflammation (C0021368), 
respectively. 
 
 
Evaluation of DEB: Comparison with Expert Opinion and SIDER as “Gold Standard” 
SIDER is an open-source database of medication indications and adverse drug 
effects (described in more detail above) (86).  We did not integrate SIDER content into 
DEB, but instead used it as a ―gold standard‖ external reference for evaluation as 
described below. 
We downloaded the SIDER Side Effect Resource files ―adverse_effects_raw‖, 
―indications_raw‖, and ―label_mapping‖ from the SIDER website (89).  The 
adverse_effects_raw and indications_raw files contained AE and IND concepts, 
respectively, and the drug label ID from which they were extracted.   The label_mapping 
files contained the label IDs, as well as the brand name, generic name, and PUBCHEM 
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STITCH ID for the drug.  The data was in tab separated value format that we loaded into 
a MySQL database.   
To use SIDER for evaluation purposes, we mapped SIDER concepts to UMLS 
CUIs so we could directly compare the drug-finding pairs in SIDER with those in the 
DEB.  Finding concepts in SIDER were already designated by CUI, but drug names in 
the SIDER database were identified using STITCH ID, brand name, and generic name.  
We used simple string matching to compare the generic names (or the brand name if 
there was no match with the generic) with UMLS strings from the MRCONSO file.  
When there was a match, we were able to link the STITCH ID to the appropriate UMLS 
CUI for the drug concept.  We manually reviewed these matches to ensure correct 
matching whenever possible. 
The final format of the extracted SIDER information included a drug CUI, a 
finding CUI, and a field indicating whether the finding was an adverse effect or an 
indication for that drug.  It is possible for SIDER to classify a drug-finding pair as both 
an AE and an IND; in this case, we considered the SIDER pair an IND, as was done for 
the DEB.  
 
Expert Reviewer Evaluation of DEB 
To evaluate the accuracy and potential utility of DEB, we used a two-step 
approach.  First, we compared DEB to SIDER, a commonly used resource to identify 
drug adverse effects and indications. We first identified which drug-finding pairs were 
present in both the DEB and SIDER or absent in one or the other.  For drug-finding pairs 
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present in both SIDER and the DEB, we determined if both resources categorized the 
relationship in the same manner as an IND or AE, or if they differed.   
Four Vanderbilt faculty physician reviewers, each board-certified in internal 
medicine and with over 10 years of clinical experience, each rated 200 drug-finding pairs 
from the DEB. Reviewers were blinded to the DEB and SIDER categorizations of the 
pairs. We provided to each reviewer a Microsoft Excel spreadsheet containing their 
unique set 200 drug-finding pairs and, for each pair, links that enabled them, with one 
click, to search either PubMed or Google for information regarding the pair.  The experts 
received instructions to mark the relationship of the pair as either AE, IND, Both (see 
explanation below), or Neither. They also could fill out an optional field for comments 
about the relationship or the information they found.  Of the 200 pairs given to each 
reviewer, 25 were the same across all reviewers (to calculate inter-rater agreement), 75 
were randomly chosen from drug-finding pairs where the DEB categorization differed 
from SIDER, and 100 were chosen at random from the overall DEB segment that did not 
overlap with SIDER (i.e., SIDER did not contain the pairing).  To find inter-rater 
agreement, we calculated both Cohen’s Kappa for each pairwise combination of 
reviewers and Fleiss’ Kappa for the entire group.   
Due to the nature of indications and adverse effects in clinical practice, a finding 
concept can represent both an AE and an IND. As previously discussed, this was often 
the case in the MEDLINE classifications in MRCOC.   For example, warfarin might be 
used for stroke prophylaxis in a patient with atrial fibrillation, but when given in 
excessive dosages, warfarin can cause a stroke through intra-cerebral hemorrhage.  Even 
though both DEB and SIDER classify a drug-finding pair as one or the other, reviewers 
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were allowed to classify pairs as ―both‖ or ―neither‖. The ―neither‖ category implied that 
the pair was an incorrect association or, in some cases, one that was too broad or 
nonsensical. 
We compiled and compared the expert reviewers’ comments to identify any 
common themes regarding problems with DEB.  Additionally, one reviewer empirically 
analyzed some of the drug-finding pairs that occurred in DEB alone, SIDER alone, and 
both DEB and SIDER to assess the similarities and differences among the 
categorizations. 
 
Results 
 
MRCOC Component of DEB 
From the MRCOC table, our DEB construction algorithms extracted 423,776 
entries that contained paired drug and finding concepts matching our semantic type 
criteria.  These entries represented approximately 100,000 drug-finding pairs since there 
were typically four UMLS entries for each pair: an entry in each of two directions from 
MBD and from MED sources).  After combining entries into drug-finding pairs, 
generalizing and combining drugs concepts, and rejecting pairs that did not have our 
required MeSH subheadings, the algorithms retained 65,930 distinct pairs consisting of 
1825 unique drugs and 3121 unique findings. 
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NDF-RT Component of DEB 
From the NDF-RT, the DEB construction algorithms extracted 51,132 entries in 
which one of the relevant relationships was present between a drug concept and a finding 
concept. These entries represented ~25,500 drug-finding pairs (one entry for each 
direction of the relationship).  After generalizing and combining drug concepts, the 
algorithms retained 7870 pairs consisting of 2084 unique drugs and 1033 unique findings.  
This included 273 ―has physiological effect‖ relationships, 622 ―induces‖ relationships, 
5483 ―may prevent‖ relationships, and 44,934 ―may treat‖ relationships.   
 
SPL Component of DEB 
From the SPLs, the DEB construction algorithms identified 958 single active 
ingredient drugs.  Using UMLS strings to map these drugs to CUIs, the algorithms were 
able to match 888 drugs.  After generalizing and combining drug concepts, the algorithms 
retained 758 distinct drugs.  Overall, the algorithms extracted 6980 unique finding 
concepts from the SPLs as both AEs and INDs.  This resulted in 81,223 distinct drug-
finding pairs. 
 
Combined DEB 
After combining information from the three DEB data sources, the resulting DEB 
evidence base contained 137,194 drug-finding pairs consisting of 3242 unique drugs and 
8266 unique findings.  There were 132,629 pairs (97%) with data from only one source, 
4086 pairs (~3%) where data came from two knowledge sources, and 479 pairs  (< 1%) 
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where data came from all three sources.  Overall, the DEB classified 79,284 pairs as AEs 
and 57,854 pairs as INDs. 
 
SIDER 
After mapping SIDER information to UMLS CUIs and generalizing and 
combining drug concepts (in the manner done for the DEB), we retained 63,857 SIDER 
drug-finding pairs consisting of 871 unique drugs and 1688 unique findings.  This 
included 58,024 pairs as AEs and 5833 pairs as INDs. 
 
 
 
 
Figure 6. Venn diagram illustrating drug-finding pairs in DEB and SIDER. 
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SIDER Evaluation 
In comparing the DEB with the information in SIDER, we determined that 34,406 
pairs were in both SIDER and DEB (see Figure 6).  This represented 54% of extracted 
SIDER findings and 25% of DEB.  The other 29,451 pairs in SIDER did not appear in the 
DEB (see below).  Of the pairs in both sources, SIDER and the DEB agreed on 33,398 
(97%) categorizations (as IND or AE) and disagreed on 1008 (3%). 
 
Expert Reviewer Evaluations 
Of the 200 drug-finding pairs reviewed by each reviewer, 25 were the same for 
each reviewer.  Using their ratings of the common drug-finding pairs, we calculated inter-
rater agreements. We used Cohen’s Kappa for each pairwise combination between each 
of the four reviewers, and we used Fleiss’ Kappa to measure overall agreement.  Since 
determining whether a finding is an AE or IND can be subjective, we also calculated 
Kappa separately for those drug-finding pairs on which no reviewer had indicated a 
―both‖ relationship, in order to estimate the degree of agreement on the less ambiguous 
pairs.  Results are shown in Table 1 below. 
 
Table 1. Agreement between Reviewers. 
Reviewers 
N=25 (all) N=21 (“Both” removed) 
Kappa p-value 95% CI Kappa p-value 95% CI 
1 and 2 0.11 0.374 (-0.13, 0.36) 0.17 0.312 (-0.16, 0.49) 
1 and 3 0.58 <0.001 (0.28, 0.87) 0.59 <0.001 (0.27, 0.90) 
1 and 4 0.43 <0.001 (0.18, 0.68) 0.59 <0.001 (0.27, 0.90) 
2 and 3 0.13 0.291 (-0.11, 0.38) 0.18 0.273 (-0.14, 0.49) 
2 and 4 0.47 <0.001 (0.23, 0.71) 0.34 0.034 (0.03, 0.66) 
3 and 4 0.50 <0.001 (0.25, 0.75) 0.67 <0.001 (0.36, 0.99) 
1, 2, 3,  & 4 0.36 <0.001 (0.26, 0.47) 0.42 <0.001 (0.29, 0.55) 
1, 3, & 4 0.50 <0.001 (0.34, 0.65) 0.62 <0.001 (0.43, 0.80) 
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Of the 200 drug-finding pairs reviewed by each of the four reviewers, 75 were 
from a random sample of those pairs where the DEB categorization of IND vs. AE 
disagreed with that of SIDER (this sample included 300 of the total of 1008 overall DEB-
SIDER classification disagreements).  Table 2 below shows ratings on these 300 
discrepant pairs by our reviewers.  All the four reviewers agreed with DEB more often 
than SIDER (P≤0.01 for the group as a whole).  On average, reviewers agreed with DEB 
30% more of the time when the disagreement occurred between DEB and SIDER (95% 
CI was 20% to 40%). 
 
Table 2. Reviews on Disagreements between DEB and SIDER. 
Rev 
Agreed w/ DEB 
(Pr1) 
Agreed w/ SIDER 
(Pr2) 
Both 
(Pr3) 
Neither 
(Pr4) 
Pr1 – Pr2 H0 : Pr1= Pr2 
Est. 95% CI P-value 
1 0.64 (48/75) 0.28 (21/75) 0.03 (2/75) 0.05 (4/75) 0.36 (0.16, 0.56) <0.001 
2 0.55 (41/75) 0.24 (18/75) 0.09 (7/75) 0.12 (9/75) 0.31 (0.12, 0.50) 0.001 
3 0.53 (40/75 0.28 (21/75) 0.01 (1/75) 0.17 (13/75) 0.25 (0.06, 0.45) 0.011 
4 0.52 (39/75) 0.25 (19/75) 0.07 (5/75) 0.16 (12/75) 0.27 (0.08, 0.46) 0.006 
Avg 0.56 0.26 0.05 0.13 0.30 (0.20, 0.40) <0.001 
 
 
Of the 200 drug-finding pairs each expert reviewed, 100 were from a random 
sample from DEB that did not overlap with SIDER.  Results of categorizations for each 
reviewer are shown in the below in Tables 3 and 4.  All the reviewers significantly agreed 
with DEB on more than 42% of the pairs and disagreed on less than 25% of the pairs.  On 
average, reviewers were 9-fold more likely to agree with the DEB categorization than to 
disagree with it (95% CI was 5.6 to 20.9 fold).  Note that DEB did not include ―both‖ or 
―neither‖ options in its internal categorizations. 
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Table 3. Reviewers’ categorizations of random selection from DEB/SIDER overlap. 
Reviewer Agreed w/ DEB 
(Pr1) 
Disagreed w/ DEB 
(Pr2) 
Both (Pr3) Neither (Pr4) 
1 0.78 (78/100) 0.16 (16/100) 0.03 (3/100) 0.03 (3/100) 
2 0.52 (52/100) 0.11 (11/100) 0.08 (8/100) 0.29 (29/100) 
3 0.58 (58/100) 0.08 (8/100) 0.00 (0/100) 0.34 (34/100) 
4 0.57 (57/100) 0.03 (3/100) 0.02 (2/100) 0.38 (38/100) 
On avg. 0.61 0.10 .0.3 0.26 
 
Table 4. Reviewers’ agreements (continued from Table 3). 
Reviewer 
Pr1 Pr2 Pr1 / Pr2 
Estimate 95% CI Estimate 95% CI Estimate 95% CI 
1 0.78 (0.70, 0.86) 0.16 (0.09, 0.24) 4.88 (3.00, 9.33) 
2 0.52 (0.42, 0.62) 0.11 (0.05, 0.17) 4.73 ( 2.71, 10.60) 
3 0.58 (0.48, 0.67) 0.08 (0.03, 0.14) 7.25 ( 3.79, 20.36) 
4 0.57 (0.48, 0.66) 0.03 (0.00, 0.07) 19.00 ( 7.86, 63.00) 
On avg. 0.61 (0.57, 0.66) 0.10 (0.07, 0.12) 8.96 ( 5.60, 20.86) 
 
 
Table 5 shows an expert clinician’s categorizations of the DEB and SIDER drug-
finding pair classifications for one drug, abacavir. The reviewer, in the comments field, 
noted how often apparent differences might be due to use of differing terms for similar 
findings. 
 
Table 5.  DEB/SIDER classifications for the drug abacavir. 
Finding SIDE
R 
DEB Comments Discrepancy 
Count 
Musculoskeletal pain AE AE See "myalgia" below  
Abdominal Pain AE AE   
Acidosis AE  See below 1 
Acidosis, Lactic  AE See above 2 
Acquired 
Immunodeficiency 
Syndrome 
IND IND   
Adverse event  AE Bad category 3 
Alanine aminotransferase 
increased 
 AE See "Liver function …" and "Increased 
liver function …" below 
4 
Allergy Severity - Severe  AE See below 5 
anaphylaxis AE  See above 6 
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Table 5 (continued).  DEB/SIDER classifications for the drug abacavir. 
Anemia AE AE   
Anorexia AE   7 
Anxiety AE   8 
Arthralgia AE  See "Musculoskeletal Pain" above 9 
Blind Vision  AE  10 
Bronchitis AE AE   
Chills AE AE   
Conjunctivitis AE   11 
Coughing AE  See "Bronchitis" above 12 
Creatine phosphokinase 
increased 
 AE  13 
Depressive disorder  AE  14 
Diarrhea AE AE See also "Severe Diarrhea" below  
Dizziness AE AE bad category  
Dream disorder  AE See "Sleep Disorders" below 15 
Dyspnea AE  See "Shortness of breath" below 16 
Edema AE   17 
Enlargement of lymph 
nodes 
AE   18 
Erythema Multiforme AE AE   
Exanthema AE AE See multiple skin disorders listed 
elsewhere 
 
Fatigue AE AE bad category  
Fatty Liver AE AE   
Fever AE AE   
Gastritis AE AE See below  
Gastroenteritis AE  See above 19 
gastrointestinal sign  AE See above 20 
Gastrointestinal 
symptoms NOS 
 AE See above 21 
Headache AE AE   
HIV Infections AE IND MAJOR error in SIDER; See "Acquired 
Immunodeficiency …" above 
 
Hyperamylasemia AE AE See pancreatitis below  
Hyperglycemia AE AE   
Hypersensitivity IND IND Looks like ERROR in both unless better 
explained 
 
Hypertriglyceridemia AE AE   
Hypotension AE  ?? Part of "Anaphylaxis" above ?? Or 
independent ?? 
22 
Infection IND  bad category 23 
Infective pharyngitis  AE See "pharyngitis" below 24 
Influenza AE  See "viral respiratory infection" below 25 
Kidney Failure AE   26 
Leukopenia AE AE See low individual WBC type 
descriptors also 
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Table 5 (continued).  DEB/SIDER classifications for the drug abacavir. 
Lipid Metabolism 
Disorders 
AE  See "Hypertriglyceridemia" above 27 
Liver Failure AE  See below 28 
Liver function tests 
abnormal finding 
 AE See above AND below "Raised liver …" 29 
Lymphopenia AE  See "Leukopenia" above 30 
Malaise AE AE bad category  
Migraine Disorders AE AE   
Morular Metaplasia of the 
Endometrium 
 AE ?? Bad category ?? 31 
Myalgia AE  See "Musculoskeletal Pain" above 32 
Myocardial Infarction  AE  33 
Nasal infection  AE  34 
Nausea AE AE   
Neutropenia AE AE See "Leukopenia" above  
Oral Ulcer AE   35 
Pain AE AE bad category  
Pancreatitis AE AE   
Paresthesia AE   36 
Pharyngitis AE  See "infective pharyngitis" above 37 
Pneumonia AE AE   
Raised liver function tests AE  See "Liver function …" and "Alanine 
Amino…"  above 
38 
Respiratory Distress 
Syndrome, Adult 
AE  See below 39 
Respiratory Failure AE  See above 40 
Severe diarrhea  AE See also "Diarrhea" above 41 
Shortness of Breath AE  See "Dyspnea" above 42 
Sleep Disorders AE AE See below  
Sleeplessness AE  See above 43 
Sore Throat AE  See "Pharyngitis" above and "Infective 
Pharyngitis" above 
44 
Spondylolisthesis, grade 2  AE ?? Bad category ?? 45 
Stevens-Johnson 
Syndrome 
AE AE   
Therapy naive  AE bad category 46 
Thrombocytopenia AE AE   
Toxic Epidermal 
Necrolysis 
AE AE   
Urticaria AE  See "Allergy" above 47 
Viral respiratory infection  AE See "Influenza" above 48 
Vomiting AE AE   
White blood cell count 
increased 
 AE  49 
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Of the 49 apparent discrepancies (enumerated in Table 5) where only DEB or 
only SIDER listed a finding associated with the drug abacavir, the expert marked four as 
―bad category‖ errors in for finding concepts.  Of the remaining 45 discrepancies, the 
expert identified 16 where collapse of findings into homogenous terminology would 
eliminate discrepancies.  These 16 collapsible discrepancies plus 4 bad categories 
represent 44% of apparent discrepancies. 
Table 6, below, shows a sample of reviewer comments.  Note that most reviewers 
only commented on those drug-finding pairs that were more ambiguous.  Matching 
determinations between DEB and the reviewer are in bold. 
 
Table 6. Sample of reviewer comments (including Reviewer and DEB determinations.) 
Drug Finding Review DEB Comments 
Acetylcysteine Heart Diseases IND IND "heart Diseases" too vague to use. N-
Acetlycysteine used to prevent damage 
due to myocardial ischemia, mostly in 
research 
almotriptan Nausea Both IND Either both, or side effect only . Can 
cause nausea, and indicated for 
migraine which has nausea as a 
symptom often 
Anti-Bacterial 
Agents 
Theileriasis Neither IND "anti-bacterial agents" too broad; 
disease only affects CATTLE 
Anticoagulants Compartment 
syndromes 
AE AE a stretch, sort of 
Anticonvulsants Ketogenic Diet Neither IND both are tx for seizures 
Antioxidants Pathologic 
Neovascularization 
IND IND "Antioxidants" too general, and 
pathologic neovasc is not much better; 
Bupropion Weight Gain IND IND Indirect association, helps with 
smoking  but prevents wt gain 
experienced during smok. Cessation 
Cardiovascular 
Agents 
Atrial Fibrillation Both IND "CV agents" category too general; 
mostly treat; digoxin  does both 
Cardiovascular 
Agents 
Atrial Fibrillation IND IND med too general 
Chlormethiazole Alcoholic Intoxication, 
Chronic 
AE IND Fatal in alcoholics 
Cisplatin Horse Diseases Neither IND "horse diseases" not a relevant term -- 
drop it. 
Corticotropin Contracture Neither AE Corticotropin is a natural substance in 
humans -- its deficiency can lead to 
flexion contractures 
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Table 6 (continued). Sample of reviewer comments. 
Dantrolene Tachypnea Neither IND Dantrolene treats malignant 
hyperthermia, itself a very rare cause of 
tachypnea 
Dantrolene Tachypnea Neither IND Doesn't treat tachypnea, rather malig 
hyerthermia which presents with 
tachypnea 
Dantrolene Tachypnea IND IND for MH 
Dextrothyroxine 
Sodium 
Coronary 
Arteriosclerosis 
Neither IND Ancient form of lipid-lowering therapy 
no longer used, especially for CAD 
Estrogens Cerebrovascular 
accident 
AE IND Very weak association in the literature.  
Excitatory 
Amino Acid 
Antagonists 
Tobacco Use Disorder IND IND Mostly research studies; terms both too 
vague 
Goserelin Neoplasms IND AE "Neoplasms" too broad-used in treating 
breast/prostate cancers 
Haloperidol Vomiting Neither IND could be AE but rare 
Heparin Asthma IND IND Weak association 
Hydrocortisone Erythema Neither AE Could say this is an indication, or an 
effect, but I think neither is best 
Iloprost Personal Satisfaction Neither AE "Personal satisfaction" is a "junk" term 
in UMLS for our purposes 
imiquimod Carcinoma IND IND "Carcinoma" too general - this is a 
topical agent used in various forms of 
skin cancer 
Lactulose Diarrhea AE IND Both desired and adverse effect 
Levalbuterol Adverse event Neither AE Adverse Event is too nonspecific, 
ignore this term 
Lidocaine 
Hydrochloride 
Drug toxicity Neither IND too broad 
Metformin Hepatitis AE IND rare 
Nicotine Pain Both IND Too complex -- "nicotinic receptors" 
involved in neural pain pathways, 
smoking interacts with pain, etc. 
Nitric Oxide Lung diseases IND IND "Lung diseases" too nonspecific -- it 
only treats pulmonary hypertension and 
rare other disorders 
Omeprazole Vomiting IND AE If GERD/PUD is causing vomiting 
Phenylalanine Cognition Disorders IND AE unsure 
Praziquantel Sheep Diseases Neither IND huh? 
Psychotropic 
Drugs 
Substance-Related 
Disorders 
IND AE "Substance-related disorders" and 
psychotropic drugs -- both too broad as 
categories 
Raloxifene Breast tenderness Neither AE Breast tenderness only occurs when this 
drug is combined with estrogen therapy 
repaglinide CARDIAC EVENT AE AE "CARDIAC EVENT" too nonspecific 
of a term 
Zinc Skin Neoplasms Neither IND unsure 
Zinc Skin Neoplasms IND IND Zinc oxide sunblock creams used in 
preventing later skin cancer 
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Discussion & Limitations 
 
Summary 
 The DEB automatically combines drug indication and adverse effect information 
from multiple sources.  These sources are frequently updated, and since DEB is 
constructed algorithmically without manual intervention, it can be regenerated in a fully 
automated manner to take advantage of updates in the knowledge sources.  We have 
shown that the DEB is comparable in several ways to SIDER, a popular resource for 
drug-finding information, for the drug-finding pairs that they have in common.  
Additionally, our expert review suggests that the DEB may be more accurate when 
SIDER and DEB disagree on IND/AE determination.  While there are disparities (e.g., 
use of different synonyms to denote the same findings) among many of the UMLS 
concepts in DEB and SIDER, there appears to be general agreement on broad concepts.  
It appears that future work on condensing clinical synonyms into a canonical list of 
concepts should be able to address these disparities.  We discuss our specific results 
below. 
 
Direct Comparison with SIDER 
For the drug-finding pairs present in both DEB and SIDER (34,406), there was 
97% agreement (33,398) on whether the pair represented an AE or IND. These results 
suggest that DEB is comparable to SIDER for the drug-finding pairs they have in 
common. We cannot draw conclusions regarding the accuracy or reliability of the 
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remaining portions of DEB from these results alone.  We discuss experts’ judgments 
regarding the disagreements below. 
 
DEB Evaluation: Inter-rater reliability 
Landis and Koch (92) gave one of the most popularly used interpretations of 
Kappa, however it is not universally accepted (93).  They reported that a Kappa less than 
or equal to zero indicates poor agreement; a Kappa of 0.01-0.20, slight agreement; 0.21-
0.40, fair agreement; 0.41-0.60, moderate agreement; 0.61-0.80, substantial agreement; 
and almost perfect agreement at 0.81-1.00. 
For the 25 pairs that the reviewers rated in common, the pairwise Kappas between 
reviewers range from slight agreement to moderate agreement, with values implying 
moderate agreement.  However, if one does not consider the pairs that reviewers rated as 
both – that is, removing those pairs that were ambiguous – some of the pairwise Kappas 
move into the range of substantial agreement.  Similarly, for Fleiss’ Kappa over all 
reviewers, agreement ranges from fair (Kappa=0.36, p < 0.001) to moderate 
(Kappa=0.42, p < 0.001).  We believe that this illustrates a general agreement between 
reviewers, but further illustrates the difficulty of determining the nature of a drug-finding 
pair relationship.  We believe that further research might take advantage of the 
information used in constructing the DEB to examine the differences in the INDscore and 
AEscore for each drug pair, along with the number of sources from which the DEB 
derived a drug-finding pair relationship, to incorporate a certainty metric into DEB.  
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DEB Evaluation: Expert Review of DEB/SIDER Disagreements 
Our expert reviewers examined a random sample of 300 pairs (75 for each 
reviewer) taken from the overall set of 1008 drug-finding pairs where the DEB and 
SIDER categorizations (IND vs. AE) disagreed.  While the reviewers agreed with DEB 
between 53% and 72% of the time, they only agreed with SIDER between 24% and 28% 
of the time.  On average, reviewers agreed with DEB 30% more of the time when DEB 
and SIDER disagreed (P≤0.01).  We believe this suggests that a drug-finding database 
compiled from multiple sources of varying reliability might provide better information 
than using only a single, potentially unreliable source whenever information – especially 
when data regarding a specific effect are ambiguous.  Additionally, improved mapping of 
similar finding concepts to canonical ―consensus‖ terms (discussed below) could 
potentially resolve many discrepancies within the DEB and within SIDER, as well as 
between the two knowledge sources. 
 
Expert Review of Random Selection from DEB 
The expert reviewers also examined a random sample of 400 pairs (100 for each 
reviewer) from DEB that were not in SIDER.  On average, they agreed with the DEB 
categorizations of the drug-finding pairs 61% of the time.  All the reviewers significantly 
agreed with DEB on more than 42% of the pairs and only disagreed with DEB on 25% of 
the pairs.  Reviewers only selected the opposite determination (AE when DEB had IND, 
or vice versa) 10% of the time on average. While reviewers agreed with DEB a majority 
of the time (they were 9-fold more likely to agree with DEB than disagree), nearly a 
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quarter of the pairs were marked as ―neither,‖ often due to problems with vague 
terminology.    
 
DEB/SIDER Content Comparison 
As illustrated in Table 4, there are many specific CUIs that appear only in SIDER 
or DEB, but many general concepts are addressed by both sources.  Sometimes the two 
sources use similar but different CUIs for the same findings, and neither uses the CUI the 
other used.  Sometimes one source lists a specific concept and the other a more general 
concept.  Occasionally, one source will list a high-level disease process and the other will 
only list the disease process and findings of that disease, or sometimes only findings.  
Similar to how drug-concepts were mapped to a single generic ingredient, a method to 
combine similar finding concepts would be beneficial.  Table 5 suggests that up to 44% 
of apparent discrepancies in whether a finding was listed in SIDER but not in DEB or 
vice-versa might be due to using different synonyms for the same concept, or one using a 
parent concept and the other using a child concept. Future research should attempt to 
combine finding concepts in a manner analogous to the way in which we combined 
different drug concepts into a ―single ingredient generic drug concept‖ in constructing the 
DEB.  Automatically relating disease and findings concepts derived from UMLS 
vocabularies is nontrivial: not all UMLS vocabularies have robust conceptual 
relationships defined, and related concepts between different vocabularies often cannot 
be algorithmically linked. 
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Reviewer Comments 
Reviewer comments from the drug-finding pair reviews denoted that many pairs 
were ―too broad‖ (e.g., Lidocaine and Drug toxicity), ―not relevant‖ (e.g., Praziquantel 
and Sheep Diseases), ―weak associations‖ (e.g., omeprazole and tachycardia) or ―did not 
make sense‖ (e.g., Protease Inhibitor and Occupational Diseases).  We believe these 
comments indicate that metrics in addition to UMLS semantic type should be considered 
to ensure the relevance of a finding.  Concepts such as ―adverse effect‖ are too broad, 
even though the concept has one of the relevant semantic types.  Additionally, comments 
revealed that reviewers had differing mindsets; for instance, some reviewers would 
indicate that ―both‖ was a valid choice in their comment, but would select the 
predominant explanation instead (marking either AE or IND instead of ―BOTH‖ when 
rating the pair).  This inconsistency likely decreased the inter-rater agreement. 
 
Limitations 
There was surprisingly little overlap in the drug-finding pairs extracted from 
MRCOC, NDF-RT, and the SPLs.  Nearly 97% of drug-finding pairs came from one of 
the three knowledge sources (i.e., the other sources did not mention the pair).  Thus, in 
the majority of cases, no corroboration existed to ensure the reliability of the drug-finding 
pairs entered in the evidence base.  Using additional knowledge sources to ―back up‖ 
DEB entries could potentially increase its reliability.  One explanation, previously noted, 
for why the overlap between sources was low relates to our observation that similar 
finding concepts did not have the same UMLS CUI representations in different sources, 
leading to entry of multiple finding concepts for what was essentially the same concept.  
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The UMLS contains over 140 source terminologies, each containing differing concepts at 
different levels of specification and meant for different purposes.  The resulting 
discrepancies lead to imprecise matching, imprecise categorization by experts, and 
incomplete mapping among concepts within the UMLS.  One potential solution might be 
to limit the vocabulary of allowed finding concepts, possibly by using a terminology 
designed for adverse effects concepts, such as COSTART or MedDRA – after 
eliminating their own internal inconsistencies. 
While we mapped multiple similar drug concepts to a single specific generic 
ingredient, we did not do the same with finding concepts.  Concepts such as ―diabetes,‖ 
―diabetes mellitus,‖ ―diabetes mellitus Type I,‖ and ―diabetes mellitus Type II‖ are all 
related, and could represent the same finding.  It was straightforward to map drug 
concepts such as  ―Tylenol‖ and ―Acetaminophen 500mg,‖ to the generic ingredient 
―Acetaminophen,‖ but it is difficult to conclude if ―diabetes‖ the be mapped to the 
generic ―diabetes mellitus‖ concept, or to the more specific Type I or Type II concepts. 
Having multiple finding concepts for what is actually one finding results in multiple 
drug-finding pairs from disparate sources, instead of a single pair with evidence from 
multiple sources.  Future work should focus on ways to correctly generalize and combine 
these finding concepts.  
There were also several drug concepts that we could not automatically map to 
their generic ingredient concepts.  This was due to missing relationships (has_tradename, 
has_ingredient) in either RxNorm and/or the UMLS MRREL file.  While these 
relationships are present for the majority of drugs, they were not present for several 
obscure drugs or and for some recently added drug concepts. As newer versions of 
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RxNorm and UMLS correct these problems, automated re-generation of the DEB content 
could take advantage of these improvements. 
As discussed above, the reviewers considered a number of drug-finding pairs ―too 
broad‖ or ―too vague‖. A more extensive manual review to eliminate irrelevant identified 
finding concepts is one option.  Another possible solution would be to include more 
knowledge sources, such as MicroMedex or SemMED (58), and require pairs to be in at 
least two sources. From our analysis, it seems that using only the UMLS semantic type to 
define the finding concepts is not restrictive enough.  Other UMLS information, such as 
the hierarchy of concepts, might be useful in restricting finding concepts to more specific 
terms.  We plan to investigate this in future work. 
Our expert physician reviewers rated a total 725 drug-finding pairs from the DEB 
total of over 100,000 pairs.  A larger expert review sample and more detailed analysis of 
DEB might give a more complete picture of the accuracy of the DEB drug-finding pair 
categorizations.  As reviewers marked many of the drug-finding pairs in the analysis 
sample as ―both‖ or ―neither,‖ a larger sample might enable the Kappa values to indicate 
additional areas of significant inter-rater agreement.  
Having one quarter of reviewed drug-finding pairs in the DEB marked as 
irrelevant is a concern, but the primary purpose of the evidence base is for the 
classification of drug-finding pairs extracted from clinical notes.  When using the DEB 
for that purpose, we are unlikely to identify ―irrelevant‖ concepts such as ―sheep 
diseases.‖ Therefore, while the ―irrelevant‖ drug-finding pairs constitute noise in the 
DEB that should ideally be eliminated, we do not believe that their current presence 
would have a major adverse effect when applying the DEB to clinical notes. 
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Another limitation of the current study was use of NLP methods to extract 
information from the SPLs.  While NLP is an excellent tool for extracting certain types of 
discrete information from text, it can also misidentify concepts or identify concepts out of 
context.  Manual review of the SPLs discovered that indications for prescribing a 
medication were sometimes mentioned in the text of the adverse effects section.  This 
might occur, for example, when withdrawal of a medication (e.g., clonidine) exacerbates 
the underlying condition that it is used to treat (e.g., hypertension).  This phenomenon 
might cause findings to be improperly classified as adverse effects when they should be 
classified as indications.  We believe we could compensate for this type of confounding 
in the DEB by using additional knowledge sources to overcome ―false‖ signals generated 
during NLP. Additionally, generalizing symptom concepts (as discussed above) could 
help to identify when similar concepts appear in both the AE and IND sections, but are 
tagged with different CUIs.  Improvements in NLP methods may also help alleviate this 
problem in the future. 
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CHAPTER IV 
 
DRUG-FINDING CORRELATION AND ADVERSE EFFECT DISCOVERY 
 
Overview 
We analyzed Vanderbilt de-identified clinical notes to determine the feasibility of 
discovering new, unreported adverse drug effects. We did so through analysis of drug-
finding pairs mentioned in clinical notes.  This exploratory evaluation asked four general 
questions: (1) Do drug-finding pair classifications derived by applying the DEB to 
clinical notes appear at face value reasonable, i.e., do DEB categorizations match known 
drug INDs or AEs most of the time that NLP detects a pairing known to DEB? (2) For 
instances when DEB classifications appear to be incorrect, is there at least a plausible 
reason that explains the misclassification (e.g., a common diagnosis appears as false 
positive confounder, or a diagnosis causally linked to an actual indication appears as false 
positive confounder)? (3) Does there appear to be, at face value, a known clinical reason 
that can be cited to explain those clinical-note-derived drug-finding pairs that are highly 
statistically correlated (whether it be AEs, INDs, or confounding due to comorbid 
conditions)? (4) Can the NLP-based clinical note correlation algorithm rank recently 
discovered drug-AE pairs high enough to suggest future potential for more careful side 
effect discovery?  
 From the Vanderbilt SD described above, we extracted 500,000 notes that had 
tags indicating that they might possibly be History and Physical Examination (H&P) 
notes. Based on identified subsections present in the notes (as determined by SecTag), we 
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algorithmically selected a subset of the original 500,000 sample notes that were most 
likely to represent H&Ps.  From those ―more definite‖ H&Ps, we extracted finding and 
drug concepts using the Vanderbilt-developed NLP tools KMCI and MedEx, 
respectively.  We applied the same definitional requirements (based on UMLS semantic 
types) that we used in DEB construction, to refine extracted finding and drug concepts 
from the H&Ps. We also manually created a filter to remove many of the less-relevant 
concepts from consideration.  We then carried out statistical correlation analysis of drug-
finding pairs appearing in the H&P notes, and determined which pairs were represented 
in the DEB and SIDER. 
 
Materials 
This work was performed on a MacBook Pro with a 2.8 GHz Intel Core 2 Duo 
processor and 8 GB of RAM and a Linux server with forty-eight 2.2 GHz AMD Opteron 
cores and 256 GB RAM.  All data processing scripts were written in Perl. 5.10.0. The 
project used MySQL version 5.5.16 for the DEB and to store all results. 
 
Methods 
 
Source of Clinical Notes Used in Analysis 
 The de-identified Vanderbilt SD repository does not contain specific type 
identifiers for each type of clinical note entry it contains.  In the source EMR system at 
Vanderbilt, multiple types of clinical notes are all tagged with the same subtype ―HP.‖  
Therefore, the project had to determine an automated method to identifying those notes 
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that were highly likely to represent full, thorough H&Ps of the type done on admission to 
the hospital or generated during a complete evaluation during a new patient clinic visit. 
Using a set of approximately 5000 known H&Ps taken from the SD (and not included in 
the sample we later analyzed), we identified criteria to extract likely H&Ps from the SD. 
We first obtained a large group of ―candidate H&P‖ notes.  Using an SQL query, 
we extracted notes only from the HP, HPH, and HPL tables (HP, HP Hidden, and HP 
Large) in the SD, as we believed these were more likely to contain H&P notes.  We 
limited our query based on the subtype field in the SD.  We limited the search to note 
subtypes with the words ―history‖ and ―physical‖, ―HP‖, ―Admission Note‖ or some 
combination.  For this study, we focused only on adult patients and excluded any notes 
where the subtype contained the words ―pediatric,‖ ―pccu,‖ or ―nicu.‖  We also specified 
a minimum note length of 3000 characters, based on the average lengths of the known 
H&Ps we studied.  
 
where ( ( sub_type LIKE '%HISTORY%' and sub_type LIKE '%PHYSICAL%' ) 
  or ( sub_type like '%HISTORY \& PHYSICAL%' ) 
  or ( sub_type like '%HISTORY AND PHYSICAL%' ) 
  or ( sub_type like '%ADMISSION NOTE%' ) 
  or ( sub_type like '%H\&P%' ) 
  or ( sub_type = 'HP' ) 
  ) 
  and 
  ( sub_type NOT LIKE '%PEDIATRIC%' ) 
  and 
  ( sub_type NOT LIKE '%PCCU%' ) 
  and 
  ( sub_type NOT LIKE '%NICU%' ) 
  and length(content) > 3000; 
Figure 7.  Partial MySQL code used to extract notes from the SD. 
 
 
As the IRB approval restricted our study to include only 500,000 notes, we 
retrieved the 500,000 candidate H&P notes with the greatest length from our results set 
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(since we assumed longer notes were more likely to be actual H&Ps).  Programmers from 
the Vanderbilt Informatics Center responsible for the SD helped write and perform the 
query. 
The candidate H&P notes were written between February 15, 1984, and February 
28, 2011.  Due to the de-identification process, we did not have dates for each individual 
notes. 
 
Running KM/SecTag to Identify Note Sections and Finding Concepts 
 The Vanderbilt Informatics Center provided the 500,000 candidate H&P notes in 
the form of plain text files.  Files were pre-processed to remove extraneous line breaks 
and HTML/XML tags.  We ran KMCI (with the negation option on) and SecTag 
concurrently to both index the concepts in the notes and identify those sections present in 
the note.  SecTag produces as output an XML document containing tags identifying 
where H&P sections begin and end throughout the note.  KMCI produces multiple output 
files; we used the ―detailedcuis.txt‖ output file.  It contains one entry per line for each 
concept identified in the note, along with information such as CUI, semantic type, 
whether or not the concept was negated, and (when run with SecTag) in what H&P 
section the concept appeared. 
 
Identifying “Adequately Extensive” H&Ps from the Candidate H&P Set 
 To identify adequately extensive, more certain H&Ps from among the 500,000 
candidate H&Ps, we utilized the SecTag output indicating which sections were present in 
each candidate note.  Using expert-guided empirical analyses of 5000 notes not part of 
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the 500,000 samples, we explored multiple criteria to determine which sections should be 
present in a high-quality (as defined above) H&P note.  The expert examined notes using 
differing empirical criteria over multiple iterations. We arrived at three potential criteria 
that could potentially identify an ―adequately extensive H&P note‖ (according to our 
criteria, shown below in Table 7).  To further ensure that a note was an H&P, we required 
it to satisfy at least two of the three criteria. 
 
Table 7. Three section criteria to identify likely H&P notes. 
Criterion Sections Present in the note 
1 (History of Present Illness OR Past Medical History) AND Physical Exam 
2 
At least 4 of (Review of Systems | Chief Complaint | Assessment | Family 
Medical History | Medications | (History of Present Illness | Past Medical 
History)) 
3 
At least 5 of (Vital Signs | Pulmonary Exam | Cardiovascular Exam | 
Neurological Exam | HEENT Exam | Abdominal Exam | Lymphatic Exam | 
Extremity Exam | General Exam) 
 
 
Running MedEx to Identify Drug Concepts 
 From the 366,545 H&Ps notes that appeared to be ―adequately extensive‖ H&Ps 
as determined by applying our criteria, we extracted H&P sub-sections that were deemed 
to contain the patient’s current or recent medications (i.e., past medications, as opposed 
to medications that the clinician planned to prescribe as a result of the examination). 
Thus, the medication list identified drugs the patient was taking, or had very recently 
take, at the time of generation of the note (corresponding to admission for inpatient 
H&Ps).  We identified the following H&P sections as likely sites for past or current 
medications: 
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 History of Present Illness 
 Past Medical History 
 Chief Complaint 
 Problem List 
 Medications 
 Current Medications 
 Admission Medications 
 Medication History 
 Medications Outside Hospital 
 Medications at Transfer 
 Inpatient Medications 
 Outpatient Medications 
 Current Antibiotics 
 Oncologic History 
 Personal and Social History 
 Ethanol Use 
 Tobacco Use 
For each note, we exported the text of these relevant H&P sections into a separate 
file that we then used as input for MedEx.  MedEx produces output comprised of CUIs of 
identified drug concepts, along with any associated drug signature information, such as 
dose, route, and strength.  To ensure that a MedEx-identified drug concept actually 
represented a medication taken by the patient, we required that the H&P note from which 
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the drug name was extracted had to mention in addition at least one item of signature 
information. 
 
Identifying and counting drug-finding pairs within H&P notes 
 For each H&P, we constructed a patient’s finding list from the KMCI 
“detailedcuis.txt” output and a patient’s medication list from the MedEx output, as 
follows: 
We added a finding to the finding list if 1) it was of a relevant finding 
semantic type, as previously defined, 2) it was not in an “excluded” H&P section, and 
3) it had not been seen before in the current note.  We excluded family history 
sections since they are likely to contain findings not directly related to the patient.  
Specifically, we excluded the SecTag sections Family Medical History, Family History, 
and Mother-, Father-, Brother-, and Sister-Medical History. 
For each drug, we first generalized the drug concept to its generic ingredient 
(as described earlier).  Next, we added a drug to the medication list if 1) it was of the 
appropriate drug semantic type, as previously defined, 2) at least one of the MedEx 
signature fields (dose, strength, route, etc.) was present, and 3) it had not been seen 
before in the current note. 
Next, for each pairwise combination of a drug and a finding from the two sets 
extracted from a given H&P, the overall drug-finding count for that specific pair was 
incremented by one.  We did this over the entire set of H&P notes to generate counts 
for every drug-finding pair present in the corpus of H&Ps. 
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Since mentions of drugs and findings may occur at random as well as for a 
reason, we empirically set a threshold to only consider a drug-finding pair if it 
occurred in at least 100 of our several hundred thousand “adequately extensive” 
H&P notes.  For every drug-finding pair that appeared greater than this minimum, 
we reported the drug-count – the number of notes in which the drug concept was 
present, the finding-count – the number of notes in which the finding concept was 
present, and the co-occurrence count – the number of notes in which the pair was 
present.  For each drug-finding pair, we calculated the odds ratio and Pearson’s chi-
squared test statistic. 
 
Removal of Unsuitable Drug and Finding Concepts 
After calculating the drug-finding co-occurrences for all H&Ps, I generated the 
list of all distinct drug concepts identified, including those that occurred less than 100 
times.  Because some drugs do not have RxNorm mappings back to their generic 
ingredient, I manually reviewed this list to identify drugs not properly generalized.  I then 
coded manual mappings for these drugs into the drug-generalization procedure and re-
calculated the co-occurrences. 
Similarly, we generated a list of all distinct finding concepts identified by KMCI.  
We then sorted this list by descending count of occurrence and manually reviewed this 
list to remove finding concepts that were non-descriptive or too broad, for example 
―blood for culture,‖ ―non-specific positive culture finding,‖ ―able,‖ ―date of admission,‖ 
and ―annual exam.‖ 
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Applying the DEB to Highlight Known and Unknown Drug-Finding Pairs 
We combined the DEB described above with the SIDER information (that we 
previously used for DEB comparison) into a combined DEB/SIDER table stored in a 
MySQL database.  This combination added an additional 29,451 drug-finding pairs to the 
existing DEB of 137,194 pairs.  During the merger, in the case of a disagreement between 
SIDER and DEB, we used the categorization of a pair in the DEB (i.e., as an IND or an 
AE).  When we applied the combined drug effects database, we reported classifications 
of H&P drug-finding pairs from H&Ps using SIDER and DEB individually. 
For each of the drug-finding pairs (with a co-occurrence count greater than 100 
out of the set of 366,545 H&Ps), we checked for a matching pair in the combined 
DEB/SIDER table.  For visual analysis, we exported the pairs to a Microsoft Excel 
spreadsheet, along with the above-mentioned counts and statistics.  Each pair listed in 
DEB/SIDER as an AE was highlighted in red, while each pair listed as an IND was 
highlighted in green.  By identifying known pairs, we were better able to identify 
possibly unknown correlations. 
We used the chi-squared test statistic as the primary means of sorting pairs based 
on strength of correlation, using a target p-value cutoff of 0.001.  Since we performed the 
chi-square test for every drug finding pair, we used a Bonferroni correction to correct for 
multiple testing and reduce false positives.  This resulted in an absolute threshold of p ≤ 
1x10-8, corresponding to a chi-square value greater than or equal to 32.84.  As a 
secondary means of corroborating significant correlation, we also used an odds ratio of 
greater than two based on empirical examination of the results and confirmation from a 
statistician that an odds ratio of two was a reasonable cutoff. 
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Analysis of Drug-Finding Pair Correlations 
We examined the top (highest chi-square values) 100 drug-finding pairs ranked in 
descending (highest to lowest) order to empirically determine if our most common drug-
finding pairs fit with known clinical information.  A senior project clinician reviewed the 
list and made comments.  We also manually reviewed the automated AE/IND tagging 
from DEB for accurate classification of selected drugs.  For the selected drugs, we 
manually examined co-occurrences looking for known INDs and AEs to determine if it 
might be feasible to identify novel AEs using our methodology.  In particular, we 
identified several recent FDA drug recalls and other recently reported FDA warnings 
regarding possible adverse associations.  While DEB data focus almost exclusively on 
individual drugs, we also analyzed combined co-occurrence data for one drug class – 
HMG-CoA reductase inhibitors, popularly known as statins. To define the statin class, we 
combined the data from the following drugs:  lovastatin, simvastatin, fluvastatin, 
pravastatin, atorvastatin, cerivastatin, and rosuvastatin. We empirically examined the 
H&P drug-finding extraction results looking for interesting pairs, or pairs that illustrated 
certain limitations. 
We examined correlation results for the specific drugs rofecoxib, rosiglitazone, 
and risperidone, as well as the statin drug class and the top 100 correlations, according to 
chi-square and odds ratio.  This analysis did not use scientific metrics; instead we 
performed an informal analysis in order to identify any obvious flaws and to ascertain the 
potential for using our approach to identify novel AEs, not to make scientific 
conclusions.  In particular, we manually identified known adverse effects and indications 
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that significantly correlate with the given drugs, as well as potential confounders and 
trivial or irrelevant associations. 
 
Results 
Our original, more general SD query to identify ―candidate‖ H&P notes, 
performed by Vanderbilt Informatics Center programmers, returned 570,845 candidate 
H&P notes.  Due to IRB restrictions, we only obtained and examined the 500,000 notes 
from that set with the greatest length. We thus received the text of 496,229 ―candidate‖ 
H&P notes.  Of these, we successfully processed 494,661 notes using KMCI and SecTag.  
Not all could be processed, due to problems with the encoding of some of the notes.  
After applying our criteria for what constituted an ―adequately extensive‖ H&P note, we 
further reduced the original number to 366,600 H&Ps.  After running MedEx on their 
extracted relevant sections, we derived a final set of 366,545 H&Ps from which we 
obtained drug-finding pairs.  Some of the 366,600 H&Ps did not mention any drugs and 
were excluded from further analysis.. 
From the set of 366,545 H&P notes, we extracted a total of 809,478 drug-finding 
pairs composed of 1755 distinct drugs and 10,723 distinct findings.  After requiring a 
minimum co-occurrence count of 100 for further retention of a given drug-finding pair in 
the dataset, 75,749 drug-finding pairs remained with 666 distinct drugs and 2182 distinct 
findings. 
When we applied the combined DEB/SIDER database to classify extracted pairs, 
we identified 10,500 known AEs (8066 from DEB and 2434 only in SIDER) and 3417 
known INDs (3232 from DEB and 185 only in SIDER). 
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As noted in Methods, to compensate for the approximately 100,000 chi-square 
tests performed, the Bonferroni correction for our original threshold p-value of 0.001 
produced a new p-value threshold of 1x10-8.  For the chi-square test corresponding to 
1x10-8, a significant correlation required chi-square value of greater than 32.84.  Of the 
drug finding pairs that occurred at least 100 times, 39,304 pairs had a significant chi-
square value above our threshold and of those, 20,004 also had an odds ratio greater than 
two. 
Tables below show the highest-ranked correlations and selected results for 
rofecoxib, rosiglitazone, and risperidone, as well as for the statin drug class and the top 
40 correlations, according to chi-square and odds ratio.   
We applied DEB from Part 1 (above) to highlight the known drug-finding pairs.  
Entries highlighted in green have been tagged by DEB/SIDER as indications, entries 
highlighted in red have been tagged as AEs, and entries absent from the DEB/SIDER 
knowledge base (unknown) have white backgrounds.  Determinations that came solely 
from SIDER are listed with an asterisk.  Full results are available electronically.  
Although the chi-square values of the co-occurrences exceeded our threshold, 
indicating a statistically significant correlation between given drug and finding concepts 
in the H&Ps, the chi-square values do not imply that the pair is a ―true drug-finding pair‖ 
– that is, ―drug causes finding‖ or ―drug treats finding.‖  For example, the findings are 
often not independent, both due to synonymy and due to ―hidden‖ interrelationships 
among diseases and manifestations of those diseases that are concurrently listed as 
findings. While correlations between concepts may be statistically significant, future 
work must determine better methods or criteria to separate ―true drug-finding pairs‖ from 
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those due to known confounders (e.g., drug co-occurs often with a comorbid condition or 
related findings for the actual indicated condition). 
As stated above, our exploratory analysis addressed the following four questions 
below for the top correlations, each of our selected drugs, and the statin drug class: 
1. Do drug-finding pair classifications using DEB appear at face value 
reasonable, i.e., either matching known drug INDs or AEs most of the 
time that DEB detects a pairing? 
2. For instances when DEB classifications appear to be incorrect, is there at 
least a plausible reason that explains the misclassification (e.g., common 
diagnosis appears as false positive confounder, or diagnosis linked to 
actual indication appears as false positive confounder)? 
3. Does there appear to be, at face value, a reason behind those drug-finding 
pairs that are highly statistically correlated (whether it be AEs, INDs, or 
confounding due to comorbid conditions)? 
4. Can the correlation algorithm rank recently discovered drug-AE adverse 
effects high enough to suggest future potential for more careful side effect 
discovery? 
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Table 8. Top overall chi-square correlations (in decreasing order of chi-square). 
Drug Finding cocount odds chisq det Expert Review 
Thyroxine Hypothyroidism 13422 59.93 122517.76 IND OK 
Dornase Alfa Pancreatic Insufficiency 773 637.71 105067.22  Confounder, due to CF 
Dornase Alfa Cystic Fibrosis 1418 1658.53 90518.37 IND OK 
Tobramycin Pancreatic Insufficiency 647 368.44 72462.81  Confounder, due to CF 
Tobramycin Cystic Fibrosis 1212 346.65 64923.85 IND OK 
Allopurinol Gout 2778 79.57 61419.85 IND OK 
Insulin 
Diabetes Mellitus, Insulin-
Dependent 6179 32.76 55082.08 IND OK 
Furosemide Congestive heart failure 11955 12.04 44120.11 IND OK 
Nitroglycerin Coronary Arteriosclerosis 10379 17 42400.06 IND OK 
Colchicine Gout 1650 90.31 40544.75 IND OK 
Insulin Diabetes Mellitus 11478 10.59 36228.16 IND OK 
Lactulose Hepatic Encephalopathy 747 116.26 35601.03 IND OK 
Aspirin Coronary Arteriosclerosis 19026 6.83 35539.91  
Prophylaxis and early RX; 
IND 
Statins Hyperlipidemia 15536 7.73 35356.23 IND OK 
valacyclovir Graft-vs-Host Disease 765 96.44 33656.09  Confounder 
Albuterol Asthma 9549 10.01 32429.05 IND OK 
donepezil Dementia 901 96.29 31183.81 IND OK 
Cyclosporine Graft-vs-Host Disease 875 80.65 31032.96 IND OK 
Nitroglycerin Chest Pain 9501 11.42 29787.4 IND OK 
clopidogrel Coronary Arteriosclerosis 7289 14.41 28112.3  IND 
Illicit Drugs abnormal bruising 728 87.24 28061.35  Too broad 
Digoxin Congestive heart failure 4728 15.16 26264.48 IND OK 
Sinemet Parkinson Disease 756 115.75 25794.43  Multi-component drug; IND 
latanoprost Glaucoma 663 97.64 24977.36 IND* OK 
Statins Coronary Arteriosclerosis 15692 5.34 24296.85  IND 
mesalamine Crohn's disease 610 101.51 23912.73 IND OK 
Cocaine Cocaine Abuse 552 98.09 23906.61  Trivial 
Albuterol Exacerbation of asthma 2553 30.84 23675.4 AE Incorrect – IND 
Illicit Drugs No pain 729 65.77 23650.24  Trivial 
Aspirin Hypertensive disease 33022 4.51 23593.69 IND 
Confounder, stroke/MI 
prophylaxis 
Hydroxy-
chloroquine 
Lupus Erythematosus, 
Systemic 572 86.91 23029.24 IND OK 
mesalamine Ulcerative Colitis 423 105.89 22653.9 IND OK 
Levetiracetam Seizures 2804 37.2 22565.16 IND OK 
Insulin 
Diabetes Mellitus, Non-
Insulin-Dependent 7624 7.81 22347.89 IND OK 
Statins Hypertensive disease 30117 4.65 22289.33 IND 
Confounder, used in 
stroke/MI prophylaxis 
tamsulosin 
Benign prostatic 
hypertrophy 1430 31.73 22267.01 IND OK  
Insulin Diabetic Ketoacidosis 2014 47.45 22213.8 IND OK 
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Top Overall Correlations 
For those drug-finding pairs (in Table 8) tagged by DEB/SIDER as IND or AE, 
24 out of 27 pairs were correctly categorized according to our expert review.  The 
DEB/SIDER classification was incorrect on 3 pairs for two obvious reasons.  The pair 
Albuterol-Exacerbation from Asthma was incorrectly categorized as an AE because the 
finding concept Exacerbation from Asthma was extracted via NLP from the Adverse 
Reactions section of the SPL, but only the concept Asthma was present in the Indications 
section.  The pairs Aspirin-Hypertensive Disease and Statins-Hypertensive Disease were 
both incorrectly categorized as IND because the pairs were extracted from the MRCOC 
as indications, likely due hypertension being a comorbidity of the conditions the drugs 
were intended to treat (Coronary Artery Disease and hyperlipidemia, respectively). 
For the drugs categorized by DEB/SIDER, the reason for their correlation is 
indicated by the IND/AE determination and the reviewer comments.  Five of the 
uncategorized pairs were highly statistically correlated due to confounding by comorbid 
conditions; for example, Dornase Alfa and tobramycin are correlated with pancreatic 
insufficiency likely because pancreatic insufficiency is a result of cystic fibrosis.  Four of 
the uncategorized pairs were indications, one of which was likely missed because it was a 
multi-ingredient drug.  Three of the uncategorized pairs were too trivial or broad to be of 
use, but seemed reasonable.  For these top correlations, there were no serious AEs 
ranked.  Since indications should always co-occur with medications but adverse effects 
only rarely co-occur, it is not surprising that no AEs would be in these highest-ranked 
correlations. 
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Table 9. Top chi-square correlation results for the drug Rofecoxib. 
Drug Finding cocount odds chisq det 
rofecoxib Degenerative polyarthritis 250 3.35 318.07 IND 
rofecoxib Obesity 253 2.58 188.01  
rofecoxib Hypertensive disease 598 2 138.74 AE* 
rofecoxib Arthritis 157 2.63 135.18 IND* 
rofecoxib Prothrombin time increased 101 3.1 129.33  
rofecoxib Rheumatoid Arthritis 212 2.21 113.16 IND* 
rofecoxib Congestive heart failure 170 2.32 107.98 AE* 
rofecoxib Metabolic Diseases 216 2.1 100.06  
rofecoxib Myocardial Infarction 189 2.17 98.77 AE* 
rofecoxib Chest Pain 267 1.95 94.2 AE* 
rofecoxib Coronary Arteriosclerosis 248 1.98 92.85  
rofecoxib White blood cell count increased 233 1.96 86.54  
rofecoxib Mental Depression 238 1.9 80.1  
rofecoxib Shortness of Breath 260 1.77 66.08  
rofecoxib Lupus Erythematosus, Discoid 145 1.99 61.54  
rofecoxib Gastroesophageal reflux disease 212 1.8 60.93 AE* 
rofecoxib 
Adverse Event Associated with 
the Gastrointestinal System 107 2.1 55.35  
rofecoxib Back Pain 119 2.02 54.62 AE* 
rofecoxib Swelling 113 1.93 44.95  
rofecoxib Pain 521 1.49 44.48 IND* 
rofecoxib Hypothyroidism 129 1.83 42.89  
rofecoxib Osteoporosis 114 1.87 41.58  
rofecoxib Asthenia 137 1.76 39.41 AE* 
rofecoxib Gastrointestinal tract finding 112 1.85 39.09  
rofecoxib Diabetes Mellitus 198 1.6 36.66  
rofecoxib 
Chronic Obstructive Airway 
Disease 126 1.67 29.89  
rofecoxib Urinary tract infection 121 1.67 28.81 AE* 
rofecoxib Anemia 135 1.61 27.52  
rofecoxib Lesion 273 1.44 27.43  
rofecoxib Cerebrovascular accident 136 1.57 24.86 AE* 
. . .  
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Top Correlations for Rofecoxib 
For those drug-finding pairs in Table 9 tagged by DEB/SIDER as IND or AE, all 
are correct (94) except for two: back pain is an indication for rofecoxib, not an AE, and 
asthenia was considered too broad.  Both of these incorrect classifications came from 
SIDER, not DEB. 
For the drugs correctly categorized by DEB/SIDER, the reason for their 
correlation is indicated by the IND/AE determination.  The uncategorized findings highly 
statistically correlated with rofecoxib seem to be mostly due to confounders, such as 
obesity, mental depression, hypothyroidism, diabetes mellitus, and COPD.  Some of these 
findings, such as coronary arteriosclerosis and shortness of breath, may be associated 
with cardiovascular findings tagged by DEB/SIDER as AEs.   
As is shown in the Table 9, rofecoxib use is highly correlated with the known AE 
myocardial infarction and other cardiac affects including congestive heart failure, chest 
pain, and coronary arteriosclerosis. The known AE cerebrovascular accident, or stroke, 
also occurs often with rofecoxib use, too, but not above our current threshold for 
significance.  In this case, known AEs are present in the top correlations with rofecoxib, 
but do not stand out due to confounding and incomplete tagging of known drug-finding 
pairs. 
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Table 10. Top chi-square correlation results for the drug rosiglitazone. 
Drug Finding cocount odds chisq det 
rosiglitazone 
Diabetes Mellitus, Non-Insulin-
Dependent 608 9.11 2416.6 IND 
rosiglitazone Diabetes Mellitus 745 8.77 2334.6 IND 
rosiglitazone Hypertensive disease 1028 5.02 849.05 AE 
rosiglitazone Obesity 420 3.85 611.06  
rosiglitazone Hyperlipidemia 384 3.44 475.98  
rosiglitazone Coronary Arteriosclerosis 396 2.78 320.68  
rosiglitazone Gastroesophageal reflux disease 300 2.13 139.92  
rosiglitazone Lupus Erythematosus, Discoid 209 2.37 139.78  
rosiglitazone hypercholesterolemia 164 2.54 133.66  
rosiglitazone Anicteric 808 1.82 123.49  
rosiglitazone Arthritis 177 2.36 119.52  
rosiglitazone Angina Pectoris 116 2.71 113.74  
rosiglitazone Chronic Obstructive Airway Disease 197 2.18 107.52  
rosiglitazone Dyspnea on exertion 153 2.21 89.42  
rosiglitazone Congestive heart failure 190 2.06 88.6 AE 
rosiglitazone Shortness of Breath 326 1.79 87.12  
rosiglitazone Orthopnea 136 2.27 86.62  
rosiglitazone Myocardial Infarction 214 1.95 83.16 AE 
rosiglitazone Paroxysmal atrial tachycardia 296 1.79 81.46  
rosiglitazone Anemia 193 1.9 70.68 AE 
rosiglitazone Visual impairment 111 2.23 68.43  
rosiglitazone Stenosis 103 2.27 67  
rosiglitazone Mental Depression 273 1.73 66.77  
rosiglitazone Deep vein thrombosis of lower limb 141 2.04 66.68  
rosiglitazone Pulmonary Embolism 139 1.94 56.41  
rosiglitazone Nausea 436 1.47 44.97 AE 
rosiglitazone Cerebrovascular accident 180 1.7 44.6  
. . .  
 
 
Top Correlations for Rosiglitazone 
As shown in Table 10, of the seven highest correlated findings with the drug 
rosiglitazone categorized by DEB/SIDER, two are correctly categorized as 
indications and five are AEs (myocardial infarction and congestive heart failure are 
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suspected AEs and are included in the SPL warnings).  It is also important to note 
that MI and CHF could also be due to confounding; patients with diabetes mellitus 
are much more likely to have heart disease. 
For the other drug-finding pairs with statistically correlated with rosiglitazone, 
most appear to be confounders, including obesity, hyperlipidemia, and 
hypercholesterolemia – comorbidities that often occur with Type II diabetes mellitus.  
Suspected AEs of rosiglitazone include heart disease, stroke, bone fractures, eye damage, 
and liver damage (95).  There are statistically significant correlations with coronary 
arteriosclerosis, angina pectoris, congestive heart failure, myocardial infarction, and 
chest pain (chi-square 33.04, odds ratio 1.48).  There is also a correlation with stroke 
(cerebrovascular accident) with a chi-square value of 44.6, but an odds ratio of only 1.7, 
correlation with two known complications of diabetes, visual impairment (chi-square 
68.43, odds ratio 2.23) and diplopia (chi-square 42.44, odds ratio 1.9), and co-
occurrences below our current significance threshold with liver-related findings (jaundice 
with chi-square of 23.44, odds ratio 1.59, and liver cirrhosis with chi-square 10.84, odds 
ratio 1.3).  As before, these AE signals are present in the data, but are lost among the 
confounders. 
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Table 11. Top chi-square  correlation results for the drug Risperidone. 
Drug Finding cocount odds chisq det 
Risperidone Schizophrenia 308 42.2 8710.9 IND 
Risperidone Iron deficiency anemia 240 17.13 2914.91  
Risperidone Mental disorders 121 25.9 2422.33 IND 
Risperidone Dementia 269 13.01 2372.91 IND 
Risperidone HYPOKINESIS GLOBAL 164 16.7 2039.94  
Risperidone Poor historian 136 12.5 1253.73  
Risperidone Hypothyroidism 411 4.84 919.79 AE* 
Risperidone Epilepsy 497 4.2 829.72 IND 
Risperidone Bipolar Disorder 178 6.12 661.89 IND 
Risperidone Abnormal mental state 191 5.42 594.93  
Risperidone Diabetes Mellitus, Insulin-Dependent 202 5.06 564.57  
Risperidone Agitation 210 4.83 544.8 IND 
Risperidone Congestive heart failure 327 3.3 413.96  
Risperidone Diabetes Mellitus 444 2.83 378.33 AE 
Risperidone Hypovolemia 156 4.48 374.39  
Risperidone Psychiatric problem 169 4.27 372.97  
Risperidone Coronary Arteriosclerosis 455 2.73 354.89  
Risperidone Obesity 393 2.84 351.31 AE 
Risperidone 
Diabetes Mellitus, Non-Insulin-
Dependent 329 2.95 333.44 IND 
Risperidone Hypertensive disease 937 2.41 321.51 AE* 
Risperidone Rhonchi 115 4.62 297.31  
Risperidone Anicteric 1022 2.24 256.69  
Risperidone Alzheimer's Disease 157 3.23 215.55 IND 
Risperidone Hypoxia 138 3.39 210.24  
Risperidone Chest Pain 423 2.21 205.94 AE* 
Risperidone Eosinophilia-Myalgia Syndrome 103 3.91 205.85  
Risperidone Myocardial Infarction 297 2.41 198.11 AE* 
Risperidone Urinary hesitation 105 3.65 186.25  
Risperidone Deep vein thrombosis of lower limb 198 2.52 157.91  
Risperidone Mental Depression 358 2.01 139.78 IND 
Risperidone Confusion 145 2.67 136.59 IND 
Risperidone Tobacco use 154 2.59 134.66  
Risperidone Wheezing 162 2.48 127.85  
Risperidone Cerebrovascular accident 250 2.09 118.38 AE 
Risperidone Deglutition Disorders 169 2.32 112.72 AE 
Risperidone Liver Cirrhosis 284 1.9 99.54  
. . .  
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Top Correlations for Risperidone 
At face value, many of the DEB/SIDER categorizations of findings correlated 
with risperidone (Table 11) appear to be valid; 9/10 INDs are correct, but Diabetes 
Mellitus, Non-Insulin-Dependent is incorrect.  This categorization came from the 
MRCOC and is likely due to research in MEDLINE related to risperidone use in 
diabetics.  Of the 8 pairs classified as AEs, the 4 from DEB are correct (diabetes mellitus, 
obesity, stroke, and deglutition disorders) while the 4 from SIDER do not appear to be 
true (95). 
Risperidone’s known AEs include weight gain, diabetes, and stroke.  The 
concepts obesity and weight gain (chi-square 36.12, odds ratio 1.71), diabetes mellitus, 
diabetes mellitus, non-insulin-dependent, and cerebrovascular accident are all highly 
statistically significant, but are lost among many other ―significant‖ but confounding 
drug-finding pairs. 
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Table 12. Top chi-square correlation results for the statins, with select findings. 
Drug Finding cocount odds chisq det 
Statins Hyperlipidemia 15105 9.12 40606.57 IND 
Statins Coronary Arteriosclerosis 15198 6.29 28375.31 
 Statins Hypertensive disease 27734 5.48 23711.55 IND 
Statins hypercholesterolemia 7640 7.28 19811.4 IND 
Statins Myocardial Infarction 8130 3.52 8697.75 IND 
Statins Stenosis 4229 4.75 7460.27 
 Statins Diabetes Mellitus 9362 2.79 6471.34 IND 
Statins Peripheral Vascular Diseases 3601 4.52 6048.25 IND 
Statins Diabetes Mellitus, Non-Insulin-Dependent 6909 2.98 5787.67 IND 
Statins Angina Pectoris 3632 4 5192.13 IND 
Statins Congestive heart failure 6180 2.94 5128.04 
 Statins Cerebrovascular accident 6428 2.64 4328.46 IND 
Statins Epilepsy 7264 2.5 4260.15 
 Statins Ischemic cardiomyopathy 1776 5.95 4198.61 
 Statins Retina-normal 1438 6.7 3834.55 
 Statins Chest Pain 9109 2.14 3520.67 
 Statins Ischemia 3179 3.34 3519.73 IND 
Statins Arthritis 4769 2.64 3341.17 
 Statins Dyslipidemias 1783 4.73 3278.79 IND 
Statins Congenital leukocyte adherence deficiency 1612 4.82 3041.16 
 Statins Obesity 6953 2.16 2928.76 IND 
Statins Gastroesophageal reflux disease 7576 2.09 2861.92 
 Statins Mental Depression 8030 2.05 2834.82 AE 
. . .  
Statins Memory impairment 281 1.82 84.34  
Statins Memory observations  104 1.5 14.92  
Statins Memory loss 331 1.23 12.3  
. . .  
 
Top Correlations for the Statins 
Unlike the other exploratory analyses presented for single drugs, Table 12 
shows correlations for the statins drug class (as defined in Methods section).  The 
DEB categorization of findings correlated with statin use appear reasonable; of the 
top 13 drug-finding pairs categorized as indications, all seem to be correct (95).  The 
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one tagged AE, mental depression, appears to be incorrect as statins have actually 
been linked to lower risk of depression (96).   
Many of the top correlations with statins appear to be reasonable, as well; most 
are comorbid conditions or findings of those on statins.  Recently discovered AEs for 
statins include memory loss and Type II diabetes mellitus, and were the subject of a 
March 2012 FDA warning.  Memory-related AEs co-occur, including memory 
impairment, memory loss, and memory observations, but not to a statistically significant 
degree.  If these concepts were merged, however, they would likely reach our study’s 
threshold for statistical significance.  Multiple diabetes concepts appear to have a 
significant correlation, including Diabetes Mellitus, Diabetes Mellitus, Non-Insulin-
Dependent, diabetic retinopathy, diabetic neuropathies, diabetes mellitus, insulin-
dependent, diabetic, Diabetic nephropathy, proliferative diabetic retinopathy, 
nonproliferative diabetic retinopathy, diabetic foot ulcer, and diabetic gastroparesis.  
Merging these concepts would increase statistical significance, but since DEB has 
correctly tagged it as an indication, this alone might not cause the signal to stand out.  
Again, the signals of known AEs are present, suggesting future potential for adverse 
effect discovery, but they are hidden among confounders. 
 
Discussion & Limitations 
 
Summary 
While we found many ―statistically significant correlations‖ between drugs 
concepts and finding concepts in the corpus of H&P notes, many of the drug-finding 
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pairs were not truly significant in terms of representing meaningful drug knowledge – 
that is, ―drug causes finding‖ or ―drug treats finding.‖  While many known AEs were 
highly ranked in our results, we also found far too many ―statistically significant 
correlations‖ with confounders and other non-relevant concepts for this to be a viable 
method to detect novel AEs at this time.  However, as our project intended an exploratory 
analysis to assess the feasibility of this approach, we believe we were successful, and the 
future applicability of the approach will improve if one can filter the noise in the data.  
The findings in our analyses were often not independent, both due to synonymy 
and due to ―hidden‖ interrelationships among diseases and manifestations of those 
diseases that were concurrently listed as findings. While correlations between concepts 
may have been statistically significant, future work must determine better methods or 
criteria to separate ―true drug-finding pairs‖ from those due to known confounders (e.g., 
drug co-occurs often with a comorbid condition or related findings for the actual 
indicated condition). 
Among the many true and false drug-finding pairs in our results, we identified 
serious AEs associated with rofecoxib, rosiglitazone, risperidone, and the statins that 
were only discovered during post-marketing surveillance at a time years after each drug 
had been on the market.  Our results illustrate that drug-AE relationships are present in 
H&P data, if only one can find exact and reliable methods to identify them – and to verify 
such correlations through subsequent independent studies.   
We have extended the NLP-base approach use by Wang, et al., (4) on Discharge 
Summaries to show that NLP processing can identify potentially useful drug-finding 
relationships in H&P notes. We performed our analyses using a much larger number of 
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notes than Wang, et al.  Using H&P notes instead of discharge summaries enabled us to 
consider a more complete range of finding concepts as potential AEs because the H&Ps 
done at admission focus on presenting findings in detail, whereas discharge summaries 
tend to focus on the clinical course of an inpatient stay, where findings play a less critical 
role than therapies and outcomes.  Our mining of H&P finding concepts, however, also 
drastically increased the number of drug-finding pairs that derived from comorbidities, 
and potentially reduced the precision of our approach.  Additionally, by incorporating the 
retrieval of drug and finding concepts only from particular sections in the notes (5) and 
using a combined knowledge base to automatically identify adverse effects and 
indications, similar to (59), we developed the basic principles behind a method that may 
eventually automatically identify correlations and require little manual review to generate 
potential drug-AE hypotheses. 
 
Limitations 
Due to the exploratory nature of our study, the biggest limitation of our project 
was its lack of formal methods to make definitive conclusions about discovered drug-
finding pair correlations during the search for novel AEs.  As discussed above, 
confounding related to comorbidities was a significant source of noise in the data.  We 
address possible methods to reduce or eliminate such confounding in the Future Work 
section below. We further understand that indicating a potential correlation is not the 
same as showing causation. Any statistical discovery approach requires subsequent 
independent confirmation of ―interesting‖ results. Nevertheless, our exploratory analysis 
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has been successful in indicating the potential of approach to identify drug-AE 
hypotheses from EMR-derived correlation data. 
Another limitation of our study involved the ambiguous nature of the finding 
(diseases and manifestations of diseases) concepts.  There are often multiple UMLS CUIs 
with very similar meanings that appeared in the H&Ps.  For example, the concepts 
―asthma‖ and ―exacerbation of asthma‖ are obviously related, but they were treated as 
completely separate concepts in both the DEB and in terms of the co-occurrence 
calculations.  We describe a potential approach to this problem below in ―Future Work‖. 
Finally, an important limitation of our project involved the inexact nature of NLP 
processing of unconstrained text documents.  While NLP approaches allowed us to 
successfully extract discrete and computable data from clinical text, it limits our 
conclusions to what NLP tools can ―discover‖. While KMCI is very effective at correctly 
identifying UMLS finding concepts in clinical notes, there are occasional 
misidentifications.  For example, NLP systems can recognize most forms of negation, but 
not all.  When we noticed that the concept ―Exposure to HIV infection‖ (C0262514) 
seemed to occur too often in our dataset, we examined the KMCI output files.  Often, 
KMCI would identify the concept in H&Ps that state ―HIV exposure negative‖ or ―HIV: 
negative.‖ No NLP system is perfect, and such limitations must be recognized. An NLP 
system typically requires pre-specification of ―target concepts‖ to identify; it is likely that 
a more constrained set of potential findings than that specified in the UMLS might have 
produced different results. 
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CHAPTER V 
 
CONCLUSION 
 
 The goal of this project was to explore the feasibility of adverse drug effect 
discovery from the data mining of clinical notes.  We have shown that a large corpus of 
H&Ps has embedded signals that are potentially useful for AE discovery. Further 
statistical and biomedical research must conclusively prove any adverse effects 
discovered through any retrospective correlation analysis. One cannot draw conclusions 
solely from disproportionality analysis or other methods; definitive proof of an adverse 
effect can only come from a convergence of experimental, clinical, and statistical 
research (33). Our approach, while promising, cannot be used ―as is‖ to detect new 
adverse effects.  
The project has also demonstrated the potential value of using H&P notes as a 
source of medication and finding-related information.  This extends more than a decade 
of previous NLP work involving analysis of clinical documents. Unlike spontaneous 
reporting systems (SRS), EHR data results in better estimates for both the ―numerator‖ 
and ―denominator.‖  Additionally, one can compare associated findings from multiple 
medications.  These both serve to compliment traditional randomized controlled trials and 
observational studies to provide large sample sizes. 
We have learned several lessons during our project.  First, identifying known 
correlations to remove them from consideration as novel AEs, such as indications and 
known AEs, is a difficult task.  Second, while using NLP and UMLS finding concepts is 
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an effective way to discretize data in natural language text, many of the concepts are too 
specific, too broad, or too vague.  Additionally, there are often too many concepts that 
refer to the same condition (―diabetes,‖ ―diabetes mellitus,‖ ―diabetes mellitus, non-
insulin-dependent,‖ etc.).  Third, false signals appear frequently since a drug often co-
occurs not only with the finding that it is used to treat, but also with other findings that 
co-occur with the finding in questions (for example, insulin treats diabetes, but co-occurs 
frequently with heart disease since heart disease often accompanies diabetes).  Fourth, 
using a hard cutoff for significance based upon chi-square and odds ratios causes many 
potentially meaningless correlations to appear statistically significant; other measures of 
meaningful significance should be explored.  We discuss possible ways to address these 
problems in the following section. 
 
Future Work 
 
Known Correlations 
For novel adverse effect signals to better stand out, it would be useful to be able 
to better identify known reasons for drug-finding correlation.  We believe the addition of 
more knowledge sources would improve the DEB.  Sources such as the AERS and 
SemMed, as used by (58), could enhance the accuracy of DEB.  Additionally, a certainty 
metric, based upon the number of sources from which a drug-finding pair has been 
extracted, would also improve the usefulness of tagging known correlations.  The greatest 
improvement in the DEB, however, would come from the development of a method to 
generalize and combine finding concepts (discussed below). 
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Finding Concept Generalization 
To reduce the number of confounding concepts, it would be useful to develop a 
method for generalizing finding concepts similar to how we mapped drug concepts to 
their generic ingredient.  This would both reduce the number of distinct finding concepts 
and appropriately increase the counts for remaining relevant finding concepts.  Finding 
concepts, however, are more complex than drug concepts.  The symptoms and findings 
associated with a disease are often variable, and could be attributed to more than one 
disease concept or even to the drug as an adverse effect.  Methods for how and when to 
combine symptoms must be explored.  We plan to explore the use of the UMLS concept 
hierarchy as a possible source determining related CUIs and condensing them into a 
single CUI.  We are considering the development of expert-derived finding synonyms to 
condense finding concepts as well. 
 
Comorbidities 
Co-morbid conditions, another major source of confounding, must also be 
addressed.  Knowledge-based tools such as QMR include information on common co-
morbidities for given diseases, as well as symptoms and findings that occur with these 
diseases.  We believe this information can be applied to reduce confounding or identify 
inappropriate correlations, such as those between insulin and heart disease.  Additionally, 
data mining techniques, such as frequent itemset mining of symptoms and diseases, might 
be useful in determining which symptoms are likely due to which diseases, similar to 
(52). 
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Comparing Drug-Finding pairs of similar-indication drugs to identify AEs 
One potential method to overcome confounding using the current results (or 
similar results) might be to compare the findings associated with a given drug to the 
findings associated with a different drug (or drugs) with similar indications and similar 
target population.  By identifying which findings occur with all of the drugs in question, 
one should be able to distinguish indications or common comorbid conditions of the 
target patient population.  If certain findings occur more often with one drug than the 
others, that finding is possibly due to the drug in questions – and is a potential adverse 
effect. We believe this technique has the potential to compensate for confounding from 
comorbid conditions, but it needs to be both formalized and automated. 
 
Statistical Significance of Drug-Finding Pairs 
Finally, there were often too many pairs deemed significant for a given drugs.  
We believe it is necessary to explore the use of other statistics, or a combination of 
statistics and other methods, to improve the recognition of meaningful drug-finding pairs. 
The chi-square test, while appropriate for this type of data, often rejects the null 
hypothesis (no association between drug and finding) too often for very large samples.  
Significance cutoffs identified with volume tests developed by (97) and used in (98) have 
been shown to be more correct when dealing with clinical data.  Other data mining 
techniques and standard data mining significance measures, such as cosine similarity, lift, 
and support, should be further explored on our H&P co-occurrence data, as well (99). 
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Improved NLP 
Finally, we believe that improved NLP could also enhance the success of this 
approach towards the discovery of novel adverse effects.  We used NLP to identify 
known AEs and indications from SPLs for the construction of DEB, and to identify 
UMLS concepts present in H&P notes to calculate the co-occurrence.  Improved NLP 
could enhance the accuracy of this data.  We would like to further NLP tools that take 
advantage of the structure of clinical notes to help disambiguate concepts.  For example, 
if the word ―rub‖ is mentioned in the H&P section ―Cardiovascular Exam,‖ it is likely 
referring to a friction rub of the heart; if the same word is mentioned in the ―Orthopedic 
Exam‖ section, it is likely referring to a joint rub.  Improved concept generalization 
(above) could also be used to help develop special vocabularies for NLP tools that can 
facilitate the generalization similar finding concepts. 
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